Journal Article
. 2018 Apr; 378(22):2078-2092.
doi: 10.1056/NEJMoa1801005.

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

Leena Gandhi 1 Delvys Rodríguez-Abreu 1 Shirish Gadgeel 1 Emilio Esteban 1 Enriqueta Felip 1 Flávia De Angelis 1 Manuel Domine 1 Philip Clingan 1 Maximilian J Hochmair 1 Steven F Powell 1 Susanna Y-S Cheng 1 Helge G Bischoff 1 Nir Peled 1 Francesco Grossi 1 Ross R Jennens 1 Martin Reck 1 Rina Hui 1 Edward B Garon 1 Michael Boyer 1 Belén Rubio-Viqueira 1 Silvia Novello 1 Takayasu Kurata 1 Jhanelle E Gray 1 John Vida 1 Ziwen Wei 1 Jing Yang 1 Harry Raftopoulos 1 M Catherine Pietanza 1 Marina C Garassino 1 KEYNOTE-189 Investigators  
Affiliations
  • PMID: 29658856
  •     1676 citations

Abstract

Background: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial.

Methods: In this double-blind, phase 3 trial, we randomly assigned (in a 2:1 ratio) 616 patients with metastatic nonsquamous NSCLC without sensitizing EGFR or ALK mutations who had received no previous treatment for metastatic disease to receive pemetrexed and a platinum-based drug plus either 200 mg of pembrolizumab or placebo every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up to a total of 35 cycles plus pemetrexed maintenance therapy. Crossover to pembrolizumab monotherapy was permitted among the patients in the placebo-combination group who had verified disease progression. The primary end points were overall survival and progression-free survival, as assessed by blinded, independent central radiologic review.

Results: After a median follow-up of 10.5 months, the estimated rate of overall survival at 12 months was 69.2% (95% confidence interval [CI], 64.1 to 73.8) in the pembrolizumab-combination group versus 49.4% (95% CI, 42.1 to 56.2) in the placebo-combination group (hazard ratio for death, 0.49; 95% CI, 0.38 to 0.64; P<0.001). Improvement in overall survival was seen across all PD-L1 categories that were evaluated. Median progression-free survival was 8.8 months (95% CI, 7.6 to 9.2) in the pembrolizumab-combination group and 4.9 months (95% CI, 4.7 to 5.5) in the placebo-combination group (hazard ratio for disease progression or death, 0.52; 95% CI, 0.43 to 0.64; P<0.001). Adverse events of grade 3 or higher occurred in 67.2% of the patients in the pembrolizumab-combination group and in 65.8% of those in the placebo-combination group.

Conclusions: In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck; KEYNOTE-189 ClinicalTrials.gov number, NCT02578680 .).

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms.
Megan B Barnet, Wendy A Cooper, Michael J Boyer, Steven Kao.
J Clin Med, 2018 Jun 16; 7(6). PMID: 29904031    Free PMC article.
Review.
The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.
Nicholas Meti, Khashayar Esfahani, Nathalie A Johnson.
Cancers (Basel), 2018 Jun 20; 10(6). PMID: 29914088    Free PMC article.
Review.
Immunotherapy in the Asiatic population: any differences from Caucasian population?
Lunxi Peng, Yi-Long Wu.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951300    Free PMC article.
Review.
Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.
Jacqueline V Aredo, Sukhmani K Padda.
Curr Treat Options Oncol, 2018 Jun 29; 19(8). PMID: 29951788
Review.
Human Vaccines & Immunotherapeutics: News.
Hum Vaccin Immunother, 2018 Jun 29; 14(6). PMID: 29952740    Free PMC article.
Editorial: Controversies in the Local Management of Lung Cancer.
John M Varlotto, Giulia Veronesi.
Front Oncol, 2018 Jul 04; 8. PMID: 29967762    Free PMC article.
"Keaping" a lid on lung cancer: the Keap1-Nrf2 pathway.
Sarah A Best, Kate D Sutherland.
Cell Cycle, 2018 Jul 17; 17(14). PMID: 30009666    Free PMC article.
Review.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Julie R Brahmer, Ramaswamy Govindan, +18 authors, Roy S Herbst.
J Immunother Cancer, 2018 Jul 18; 6(1). PMID: 30012210    Free PMC article.
A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC.
Juliet A Carmichael, Daisy Wing-San Mak, Mary O'Brien.
Cancers (Basel), 2018 Jul 20; 10(7). PMID: 30021993    Free PMC article.
Review.
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Taichi Takashina, Hajime Asahina, +17 authors, Hokkaido Lung Cancer Clinical Study Group.
Int J Clin Oncol, 2018 Jul 22; 23(6). PMID: 30027464
New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.
Olivier Bylicki, Nicolas Paleiron, Gaëlle Rousseau-Bussac, Christos Chouaïd.
Onco Targets Ther, 2018 Jul 25; 11. PMID: 30038505    Free PMC article.
Review.
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer.
Yosuke Miura, Noriaki Sunaga.
Cancers (Basel), 2018 Aug 01; 10(8). PMID: 30060457    Free PMC article.
Review.
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Cancers (Basel), 2018 Aug 01; 10(8). PMID: 30060526    Free PMC article.
Highly Cited. Review.
A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer.
Muhammad Zubair Afzal, Konstantin Dragnev, Keisuke Shirai.
J Thorac Dis, 2018 Aug 03; 10(6). PMID: 30069355    Free PMC article.
Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis.
Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Joo Han Lim.
Sci Rep, 2018 Aug 08; 8(1). PMID: 30082893    Free PMC article.
Review.
Emerging therapies in advanced hepatocellular carcinoma.
Sowmini Medavaram, Yue Zhang.
Exp Hematol Oncol, 2018 Aug 09; 7. PMID: 30087805    Free PMC article.
Review.
Personalized therapy for lung cancer: striking a moving target.
Suchita Pakkala, Suresh S Ramalingam.
JCI Insight, 2018 Aug 10; 3(15). PMID: 30089719    Free PMC article.
Review.
Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials.
Rachel A Bender Ignacio, Lilie L Lin, Lakshmi Rajdev, Elizabeth Chiao.
J Natl Compr Canc Netw, 2018 Aug 14; 16(8). PMID: 30099376    Free PMC article.
Review.
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
Yiyi Yan, Anagha Bangalore Kumar, +4 authors, Haidong Dong.
Front Immunol, 2018 Aug 14; 9. PMID: 30100909    Free PMC article.
Highly Cited. Review.
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.
Beatriz Wills, Julie R Brahmer, Jarushka Naidoo.
Curr Treat Options Oncol, 2018 Aug 14; 19(9). PMID: 30101402    Free PMC article.
Review.
New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment.
Jiajia Zhang, Shafat Quadri, Christopher L Wolfgang, Lei Zheng.
Biomedicines, 2018 Aug 15; 6(3). PMID: 30104497    Free PMC article.
Review.
The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer.
Fabio Gomes, Rebecca Tay, Jaseela Chiramel, Raffaele Califano.
Drugs Aging, 2018 Aug 15; 35(9). PMID: 30105645
Review.
Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.
D E Meyers, P M Bryan, S Banerji, D G Morris.
Curr Oncol, 2018 Aug 17; 25(4). PMID: 30111979    Free PMC article.
Review.
Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
Robert Pirker.
ESMO Open, 2018 Aug 18; 3(5). PMID: 30116594    Free PMC article.
Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching.
Mary M Huerter, Apar Kishor Ganti.
J Thorac Dis, 2018 Aug 21; 10(Suppl 18). PMID: 30123559    Free PMC article.
Presence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case series.
Daiki Ogawara, Hiroshi Soda, +12 authors, Hiroshi Mukae.
Thorac Cancer, 2018 Aug 21; 9(10). PMID: 30126069    Free PMC article.
Patient performance status and cancer immunotherapy efficacy: a meta-analysis.
Melissa Bersanelli, Matteo Brighenti, +2 authors, Fausto Petrelli.
Med Oncol, 2018 Aug 22; 35(10). PMID: 30128793
Review.
Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
Jason C Hsu, Jia-Yu Lin, May-Ying Hsu, Peng-Chan Lin.
PLoS One, 2018 Aug 25; 13(8). PMID: 30142174    Free PMC article.
Adenosquamous carcinoma of the lung.
Chenghui Li, Hongyang Lu.
Onco Targets Ther, 2018 Aug 28; 11. PMID: 30147334    Free PMC article.
Review.
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Hongshu Sui, Ningxia Ma, +4 authors, Jiali Yang.
J Immunol Res, 2018 Aug 31; 2018. PMID: 30159341    Free PMC article.
Highly Cited. Review.
Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy.
David H Munn, Madhav D Sharma, Theodore S Johnson.
Cancer Res, 2018 Sep 06; 78(18). PMID: 30181177    Free PMC article.
Review.
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
Jonathan A Trujillo, Randy F Sweis, Riyue Bao, Jason J Luke.
Cancer Immunol Res, 2018 Sep 06; 6(9). PMID: 30181337    Free PMC article.
Highly Cited.
Immuno-Oncology: Emerging Targets and Combination Therapies.
Henry T Marshall, Mustafa B A Djamgoz.
Front Oncol, 2018 Sep 08; 8. PMID: 30191140    Free PMC article.
Highly Cited. Review.
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Roberto Ferrara, Laura Mezquita, +25 authors, Caroline Caramella.
JAMA Oncol, 2018 Sep 08; 4(11). PMID: 30193240    Free PMC article.
Highly Cited.
Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 (SLC18A1) in Lung Cancer.
Steven Lehrer, Peter H Rheinstein.
Cancer Genomics Proteomics, 2018 Sep 09; 15(5). PMID: 30194079    Free PMC article.
Combining immunotherapy with radiation therapy in thoracic oncology.
Shahed N Badiyan, Michael C Roach, +7 authors, Charles B Simone.
J Thorac Dis, 2018 Sep 13; 10(Suppl 21). PMID: 30206494    Free PMC article.
Review.
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
Nicolas Villanueva, Lyudmila Bazhenova.
Ther Adv Respir Dis, 2018 Sep 15; 12. PMID: 30215300    Free PMC article.
Review.
Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment.
Shohei Koyama, Izumi Nagatomo, Takashi Kijima, Atsushi Kumanogoh.
Oncotarget, 2018 Sep 18; 9(66). PMID: 30220963    Free PMC article.
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
Francesco Facchinetti, Paola Bordi, +2 authors, Marcello Tiseo.
Drug Des Devel Ther, 2018 Sep 22; 12. PMID: 30237696    Free PMC article.
Review.
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.
K G Paulson, V Voillet, +20 authors, A G Chapuis.
Nat Commun, 2018 Sep 27; 9(1). PMID: 30250229    Free PMC article.
Highly Cited.
What a dog transmissible tumor can teach us about cancer regression.
Ariberto Fassati.
Mol Cell Oncol, 2018 Sep 27; 5(4). PMID: 30250922    Free PMC article.
Highlights from the 2018 WIN Symposium, 25-26 June 2018, Paris: designing the future of precision oncology.
Will Davies.
Ecancermedicalscience, 2018 Sep 29; 12. PMID: 30263062    Free PMC article.
Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study).
Yan Xu, Li Zhang, +17 authors, Mengzhao Wang.
Thorac Cancer, 2018 Sep 29; 9(12). PMID: 30264504    Free PMC article.
DNA repair defects and implications for immunotherapy.
Katherine M Bever, Dung T Le.
J Clin Invest, 2018 Oct 03; 128(10). PMID: 30272580    Free PMC article.
Review.
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
Akio Osa, Takeshi Uenami, +30 authors, Atsushi Kumanogoh.
JCI Insight, 2018 Oct 05; 3(19). PMID: 30282824    Free PMC article.
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature.
Jan Norum, Carsten Nieder.
ESMO Open, 2018 Oct 12; 3(6). PMID: 30305940    Free PMC article.
Durvalumab in NSCLC: latest evidence and clinical potential.
Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis Paz-Ares.
Ther Adv Med Oncol, 2018 Oct 23; 10. PMID: 30344651    Free PMC article.
Review.
[Mode of action, new targets and potential biomarkers in modern immunotherapy].
J Bedke, V Stühler, T Todenhöfer, A Stenzl.
Urologe A, 2018 Oct 24; 57(11). PMID: 30350128
Review.
Atezolizumab in non-squamous non-small cell lung cancer.
Takaki Akamine, Gouji Toyokawa, Tetsuzo Tagawa, Takashi Seto.
J Thorac Dis, 2018 Oct 30; 10(Suppl 26). PMID: 30370103    Free PMC article.
Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?
Melissa Bersanelli, Fausto Petrelli.
J Thorac Dis, 2018 Oct 30; 10(Suppl 26). PMID: 30370125    Free PMC article.
Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?
Niki Karachaliou, Manuel Fernandez-Bruno, Rafael Rosell.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393600    Free PMC article.
A new era of treating advanced lung cancer is upon us.
Glen J Weiss.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393601    Free PMC article.
Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?
Monica S Chatwal, Tawee Tanvetyanon.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393603    Free PMC article.
Identification of a novel therapeutic target in driver-negative non-small cell lung cancer.
Motonobu Saito, Koji Kono, Takashi Kohno.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393606    Free PMC article.
Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy.
Umberto Malapelle, Antonino Iaccarino, Antonio Rossi.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393607    Free PMC article.
Histology versus cytology: PD-L1 testing in non-small cell lung cancer.
Nagio Takigawa, Nobuaki Ochi, Hiromichi Yamane.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393608    Free PMC article.
Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
Wolfram C M Dempke, Klaus Fenchel, Stephen P Dale.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393621    Free PMC article.
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Alfredo Addeo, Giuseppe Luigi Banna.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393624    Free PMC article.
30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?
Jacobus Adrianus Burgers, Ronald Alphons Damhuis.
ERJ Open Res, 2018 Nov 09; 4(4). PMID: 30406123    Free PMC article.
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Abhishek Tripathi, Elizabeth R Plimack.
Curr Urol Rep, 2018 Nov 09; 19(12). PMID: 30406502
Review.
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance.
Xingxiang Pu, Lin Wu, +2 authors, Bingliang Fang.
BMC Cancer, 2018 Nov 10; 18(1). PMID: 30409126    Free PMC article.
Review.
Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer.
Masaru Katoh.
J Thorac Dis, 2018 Nov 13; 10(9). PMID: 30416762    Free PMC article.
Non-small cell lung cancer: land of conquest for immunotherapy.
Enrico Munari, Giuseppe Bogina.
J Thorac Dis, 2018 Nov 13; 10(9). PMID: 30416763    Free PMC article.
Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE-189.
Sheenu Sheela, Edward S Kim, Kathryn F Mileham.
J Thorac Dis, 2018 Nov 13; 10(9). PMID: 30416764    Free PMC article.
Broader indications for checkpoint inhibitors in NSCLC.
Anders Mellemgaard.
J Thorac Dis, 2018 Nov 13; 10(9). PMID: 30416765    Free PMC article.
Immunotherapy strategy of EGFR mutant lung cancer.
Shaorong Yu, Delin Liu, +2 authors, Jifeng Feng.
Am J Cancer Res, 2018 Nov 13; 8(10). PMID: 30416860    Free PMC article.
Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
Haibo Mou, Lanfang Yu, +8 authors, Kai Wang.
BMC Cancer, 2018 Nov 14; 18(1). PMID: 30419854    Free PMC article.
Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.
Ying L Liu, Dmitriy Zamarin.
Curr Oncol Rep, 2018 Nov 14; 20(12). PMID: 30421009    Free PMC article.
Review.
The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.
Min Peng, Xing Li, +3 authors, Qi Bin Song.
Onco Targets Ther, 2018 Nov 15; 11. PMID: 30425525    Free PMC article.
Review.
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
Shirish M Gadgeel, James P Stevenson, +12 authors, Vassiliki Papadimitrakopoulou.
Lung Cancer, 2018 Nov 16; 125. PMID: 30429032    Free PMC article.
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine.
Jake R Conway, Eric Kofman, +2 authors, Eliezer Van Allen.
Genome Med, 2018 Dec 01; 10(1). PMID: 30497521    Free PMC article.
Review.
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
Simon Heeke, Paul Hofman.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505707    Free PMC article.
Review.
Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.
Lizza E Hendriks, Etienne Rouleau, Benjamin Besse.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505709    Free PMC article.
Review.
Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?
Matthew Evans, Brendan O'Sullivan, Matthew Smith, Philippe Taniere.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505713    Free PMC article.
Review.
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.
Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505714    Free PMC article.
Review.
Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.
Jan Budczies, Anja Seidel, +7 authors, Carsten Denkert.
Oncoimmunology, 2018 Dec 14; 7(12). PMID: 30524909    Free PMC article.
Determination of human γδ T cell-mediated cytotoxicity using a non-radioactive assay system.
Mohammed S O Tagod, Satoshi Mizuta, +6 authors, Yoshimasa Tanaka.
J Immunol Methods, 2019 Jan 18; 466. PMID: 30654042    Free PMC article.
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
Sayuri Miyauchi, Sangwoo S Kim, +6 authors, Andrew B Sharabi.
Clin Cancer Res, 2019 Mar 01; 25(14). PMID: 30814108    Free PMC article.
Review.
The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma.
Liang Peng, Jin-Qi Liu, Yu-Pei Chen, Jun Ma.
Br J Radiol, 2019 May 22; 92(1102). PMID: 31112398    Free PMC article.
Review.
From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.
Deepa Rangachari, Daniel B Costa.
J Clin Oncol, 2019 Jun 04; 37(28). PMID: 31154918    Free PMC article.
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
Edward B Garon, Matthew D Hellmann, +16 authors, Rina Hui.
J Clin Oncol, 2019 Jun 04; 37(28). PMID: 31154919    Free PMC article.
Highly Cited.
Application of PD-1 Blockade in Cancer Immunotherapy.
Xiaomo Wu, Zhongkai Gu, +4 authors, Xiaolong Liu.
Comput Struct Biotechnol J, 2019 Jun 18; 17. PMID: 31205619    Free PMC article.
Highly Cited. Review.
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.
F Wang, X L Wei, +22 authors, R H Xu.
Ann Oncol, 2019 Jun 27; 30(9). PMID: 31236579    Free PMC article.
Highly Cited.
Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones.
Fabien Forest, Gaelle Cote, +7 authors, Michel Péoc'h.
Virchows Arch, 2019 Jul 04; 475(6). PMID: 31267202
Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Jingjing Liu, Shuang Li, +7 authors, Ying Cheng.
J Clin Lab Anal, 2019 Jul 10; 33(8). PMID: 31282096    Free PMC article.
Highly Cited.
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.
Heng-Huan Lee, Ying-Nai Wang, +15 authors, Mien-Chie Hung.
Cancer Cell, 2019 Jul 23; 36(2). PMID: 31327656    Free PMC article.
Highly Cited.
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Yoshiya Matsumoto, Kenji Sawa, +12 authors, Tomoya Kawaguchi.
Cancer Sci, 2019 Aug 02; 110(10). PMID: 31368625    Free PMC article.
Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
Makito Miyake, Shunta Hori, +12 authors, Kiyohide Fujimoto.
Cancer Sci, 2019 Aug 07; 110(10). PMID: 31385407    Free PMC article.
Imaging of Precision Therapy for Lung Cancer: Current State of the Art.
Hyesun Park, Lynette M Sholl, +2 authors, Mizuki Nishino.
Radiology, 2019 Aug 07; 293(1). PMID: 31385753    Free PMC article.
Review.
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Motohiro Tamiya, Akihiro Tamiya, +16 authors, Daichi Fujimoto.
Invest New Drugs, 2019 Aug 09; 37(6). PMID: 31392549
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set.
Sandra D Griffith, Rebecca A Miksad, +10 authors, Amy P Abernethy.
JCO Clin Cancer Inform, 2019 Aug 14; 3. PMID: 31403818    Free PMC article.
Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report.
Masahiro Yamasaki, Kunihiko Funaishi, +5 authors, Noboru Hattori.
Medicine (Baltimore), 2019 Aug 16; 98(33). PMID: 31415404    Free PMC article.
Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.
Ying L Liu, Qin Zhou, +6 authors, Dmitriy Zamarin.
Gynecol Oncol, 2019 Aug 20; 155(1). PMID: 31421916    Free PMC article.
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Lorena Incorvaia, Daniele Fanale, +10 authors, Antonio Russo.
Adv Ther, 2019 Aug 23; 36(10). PMID: 31432460    Free PMC article.
Review.
Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?
Adrien Costantini, Paul Takam Kamga, +3 authors, Etienne Giroux Leprieur.
Cancers (Basel), 2019 Sep 01; 11(9). PMID: 31470546    Free PMC article.
Review.
In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients.
Simon Heeke, Jonathan Benzaquen, +17 authors, Paul Hofman.
Cancers (Basel), 2019 Sep 01; 11(9). PMID: 31470674    Free PMC article.
Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.
Melissa A Reimers, Kathryn E Slane, Russell K Pachynski.
Curr Urol Rep, 2019 Sep 05; 20(10). PMID: 31482315
Review.
High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Mari Tone, Takehiro Izumo, +8 authors, Hideo Kunitoh.
Thorac Cancer, 2019 Sep 05; 10(10). PMID: 31482678    Free PMC article.
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.
Catherine R Sears, Tobias Peikert, +11 authors, M Patricia Rivera.
Am J Respir Crit Care Med, 2019 Sep 14; 200(6). PMID: 31518182    Free PMC article.
[Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation 
in Non-small Cell Lung Cancer].
Xia Liu, Diansheng Zhong.
Zhongguo Fei Ai Za Zhi, 2019 Sep 19; 22(9). PMID: 31526463    Free PMC article.
Review.
Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer.
Danyang Sun, Junxun Ma, +16 authors, Yi Hu.
Cancer Immunol Immunother, 2019 Sep 20; 68(9). PMID: 31535160    Free PMC article.
Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State.
Petros Grivas, Bradley J Monk, +6 authors, Markus Moehler.
Target Oncol, 2019 Sep 20; 14(5). PMID: 31535338
Review.
Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Steven D Criss, Meghan J Mooradian, +3 authors, Chung Yin Kong.
JAMA Netw Open, 2019 Sep 26; 2(9). PMID: 31553470    Free PMC article.
Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC.
Chengxiang Yi, Yayi He, +2 authors, Peng Zhang.
Onco Targets Ther, 2019 Oct 01; 12. PMID: 31564915    Free PMC article.
Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients.
Valentina Magri, Teodor Gottfried, +6 authors, Amir Onn.
Cancer Manag Res, 2019 Oct 01; 11. PMID: 31564979    Free PMC article.
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors.
Misako Nagasaka, Nadine Abdallah, +6 authors, Ammar Sukari.
Lung Cancer (Auckl), 2019 Oct 02; 10. PMID: 31572037    Free PMC article.
Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain.
Jose M Pacheco, Dexiang Gao, D Ross Camidge.
Ann Transl Med, 2019 Oct 03; 7(Suppl 3). PMID: 31576334    Free PMC article.
Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
Willemijn S M E Theelen, Paul Baas.
Ann Transl Med, 2019 Oct 03; 7(Suppl 3). PMID: 31576347    Free PMC article.
Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Aung Myint Tun, Kyaw Zin Thein, Wai Lin Thein, Elizabeth Guevara.
Future Sci OA, 2019 Oct 15; 5(9). PMID: 31608159    Free PMC article.
Review.
Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis.
Mike Nguyen, Md Rafiqul Islam, +2 authors, Babak Tamjid.
Front Oncol, 2019 Oct 15; 9. PMID: 31608234    Free PMC article.
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness.
Haitang Yang, Shun-Qing Liang, Ralph A Schmid, Ren-Wang Peng.
Front Oncol, 2019 Oct 16; 9. PMID: 31612108    Free PMC article.
Review.
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer.
Hongge Liang, Mengzhao Wang.
Cancer Manag Res, 2019 Oct 17; 11. PMID: 31616186    Free PMC article.
Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Ronald Anderson, Annette J Theron, Bernardo L Rapoport.
Front Immunol, 2019 Oct 17; 10. PMID: 31616428    Free PMC article.
Review.
The hubris and humility of cancer pharmacology in the post immuno-oncology era.
John S Lazo.
Pharmacol Res Perspect, 2019 Oct 19; 7(6). PMID: 31624635    Free PMC article.
Review.
Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer.
Huanlan Sa, Peng Song, +3 authors, Deqiang Wang.
Onco Targets Ther, 2019 Oct 22; 12. PMID: 31632066    Free PMC article.
Hyperprogressive disease with immunotherapy: new directions.
Sally C M Lau, Natasha B Leighl.
J Thorac Dis, 2019 Oct 22; 11(Suppl 15). PMID: 31632773    Free PMC article.
KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49.
Daniel Morgensztern.
J Thorac Dis, 2019 Oct 22; 11(Suppl 15). PMID: 31632798    Free PMC article.
Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis.
Ya-Fang Huang, Wen-Jie Xie, Hai-Yu Fan, Juan Du.
Front Oncol, 2019 Oct 22; 9. PMID: 31632907    Free PMC article.
Systematic Review.
Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer.
Mari Tone, Takehiro Izumo, +6 authors, Hideo Kunitoh.
Lung Cancer Manag, 2019 Oct 28; 4(6). PMID: 31645892    Free PMC article.
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.
Muhammad Z Afzal, Konstantin Dragnev, Tayyaba Sarwar, Keisuke Shirai.
Lung Cancer Manag, 2019 Oct 28; 8(2). PMID: 31645894    Free PMC article.
Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment.
Wayne J Aston, Danika E Hope, +5 authors, W Joost Lesterhuis.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646089    Free PMC article.
Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors.
Ioannis Kaffes, Frank Szulzewsky, +19 authors, Dolores Hambardzumyan.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646100    Free PMC article.
A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice.
Sarah Lévesque, Julie Le Naour, +12 authors, Jonathan G Pol.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646107    Free PMC article.
Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression.
Cai-Ping Chen, Kun Chen, +2 authors, Hongbin Sun.
Acta Pharm Sin B, 2019 Oct 28; 9(5). PMID: 31649844    Free PMC article.
Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
David Lang, Florian Huemer, +9 authors, Bernd Lamprecht.
Target Oncol, 2019 Oct 28; 14(6). PMID: 31654203    Free PMC article.
Immunotherapy-related hepatitis: real-world experience from a tertiary centre.
Vincent Cheung, Tarun Gupta, +6 authors, Jeremy F Cobbold.
Frontline Gastroenterol, 2019 Oct 28; 10(4). PMID: 31656561    Free PMC article.
Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab.
Taro Ohba, Shinkichi Takamori, +9 authors, Mitsuhiro Takenoyama.
J Thorac Dis, 2019 Oct 28; 11(9). PMID: 31656648    Free PMC article.
Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer.
Guanghui Gao, Meng Qiao, +8 authors, Caicun Zhou.
J Thorac Dis, 2019 Oct 28; 11(9). PMID: 31656652    Free PMC article.
A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases.
Thiago Pimentel Muniz, Victor Hugo Fonseca de Jesus, +2 authors, Vladmir Cláudio Cordeiro de Lima.
J Thorac Dis, 2019 Oct 28; 11(9). PMID: 31656665    Free PMC article.
Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure?
Paolo Bironzo, Francesco Passiglia, Silvia Novello.
Ann Transl Med, 2019 Oct 28; 7(Suppl 6). PMID: 31656791    Free PMC article.
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Masaoki Ito, Carles Codony-Servat, +12 authors, Rafael Rosell.
Cell Commun Signal, 2019 Oct 30; 17(1). PMID: 31660987    Free PMC article.
Pathologic response after modern radiotherapy for non-small cell lung cancer.
Simon F Roy, Alexander V Louie, +2 authors, Houda Bahig.
Transl Lung Cancer Res, 2019 Nov 02; 8(Suppl 2). PMID: 31673516    Free PMC article.
Review.
PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer.
Andrew Bang, Jonathan D Schoenfeld, Alexander Y Sun.
Transl Lung Cancer Res, 2019 Nov 02; 8(Suppl 2). PMID: 31673518    Free PMC article.
Review.
Engineered T Cell Therapy for Cancer in the Clinic.
Lijun Zhao, Yu J Cao.
Front Immunol, 2019 Nov 05; 10. PMID: 31681259    Free PMC article.
Review.
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Farastuk Bozorgmehr, Adriane Hommertgen, +9 authors, Stefan Rieken.
BMC Cancer, 2019 Nov 11; 19(1). PMID: 31703637    Free PMC article.
The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Qing-Qing Chai, Jiang-Yang Du, Jun Zhu, Bin Wu.
Front Pharmacol, 2019 Nov 12; 10. PMID: 31708783    Free PMC article.
Systematic Review.
Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer.
Chengxiang Zhang, Xinfu Zhang, +9 authors, Yizhou Dong.
Nano Res, 2019 Nov 19; 12(4). PMID: 31737223    Free PMC article.
Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
Andrew J Piper, Kartik Sehgal, Daniel B Costa, Deepa Rangachari.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737509    Free PMC article.
KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
Jose M Pacheco.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737510    Free PMC article.
First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?
Paul Hofman.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737511    Free PMC article.
The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?
Yiqing Huang, Robert J Walsh, Ross A Soo.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737512    Free PMC article.
Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage I-III Non-small Cell Lung Cancer Patients.
Jingsi Dong, Daxing Zhu, +5 authors, Qinghua Zhou.
Front Oncol, 2019 Nov 19; 9. PMID: 31737568    Free PMC article.
Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis.
Hazem E El-Osta, Frank E Mott, +2 authors, Anita L Sabichi.
Oncoimmunology, 2019 Nov 20; 8(12). PMID: 31741764    Free PMC article.
Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients.
Takuya Aoki, Takeshi Akiba, +21 authors, Koichiro Asano.
Respir Res, 2019 Nov 23; 20(1). PMID: 31752884    Free PMC article.
Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Yuqiao Chen, Yuan Zhou, +4 authors, Wei Zhuang.
J Cancer, 2019 Nov 28; 10(25). PMID: 31772659    Free PMC article.
Review.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).
Paolo A Ascierto, Carlo Bifulco, +18 authors, Igor Puzanov.
J Immunother Cancer, 2019 Dec 01; 7(1). PMID: 31783779    Free PMC article.
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Marika Cinausero, Noemi Laprovitera, +13 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2019 Dec 05; 11. PMID: 31798692    Free PMC article.
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients.
Bin-Chi Liao, Sebastian Griesing, James Chih-Hsin Yang.
Ther Adv Med Oncol, 2019 Dec 06; 11. PMID: 31803256    Free PMC article.
Review.
Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis.
Haisam Abid, Maryam Khavandi, +2 authors, Anush Patel.
Cureus, 2019 Dec 07; 11(10). PMID: 31807385    Free PMC article.
Review.
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.
Lorenza Landi, Federica D'Incà, +18 authors, Federico Cappuzzo.
J Immunother Cancer, 2019 Nov 23; 7(1). PMID: 31752994    Free PMC article.
[A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice].
Yanxia Liu, Tongmei Zhang, +7 authors, Baolan Li.
Zhongguo Fei Ai Za Zhi, 2019 Nov 28; 22(11). PMID: 31771737    Free PMC article.
Immune checkpoint inhibitors win the 2018 Nobel Prize.
Pei-Wei Huang, John Wen-Cheng Chang.
Biomed J, 2019 Dec 01; 42(5). PMID: 31783990    Free PMC article.
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway.
Grace Wakabayashi, Yu-Ching Lee, +3 authors, Yun Yen.
J Biomed Sci, 2019 Dec 06; 26(1). PMID: 31801525    Free PMC article.
Review.
Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
Neil M Steven, Benjamin A Fisher.
Rheumatology (Oxford), 2019 Dec 10; 58(Suppl 7). PMID: 31816079    Free PMC article.
Review.
Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
Maria V Bermudez, Sophie Papa.
Rheumatology (Oxford), 2019 Dec 10; 58(Suppl 7). PMID: 31816083    Free PMC article.
Review.
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.
Carmine Carbone, Geny Piro, +9 authors, Emilio Bria.
Mediators Inflamm, 2019 Dec 13; 2019. PMID: 31827379    Free PMC article.
Review.
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer.
Jonathan W Goldman, David M Waterhouse, +7 authors, Karen Kelly.
Front Oncol, 2019 Dec 19; 9. PMID: 31850192    Free PMC article.
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
Neil J Shah, Ghassan Al-Shbool, +8 authors, Chul Kim.
J Immunother Cancer, 2019 Dec 19; 7(1). PMID: 31847881    Free PMC article.
Biomarker for personalized immunotherapy.
Si-Yang Liu, Yi-Long Wu.
Transl Lung Cancer Res, 2019 Dec 21; 8(Suppl 3). PMID: 31857954    Free PMC article.
Review.
Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients.
Philip Bonomi, Mary Jo Fidler, Palmi Shah, Jeffrey Borgia.
Cancers (Basel), 2019 Oct 28; 11(11). PMID: 31652685    Free PMC article.
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
Harish Seethapathy, Sophia Zhao, +10 authors, Meghan E Sise.
Clin J Am Soc Nephrol, 2019 Nov 02; 14(12). PMID: 31672794    Free PMC article.
Highly Cited.
Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis.
Jingli Lu, Lulu Li, +2 authors, Haiyang Meng.
Cancer Med, 2019 Nov 05; 8(18). PMID: 31679184    Free PMC article.
Systematic Review.
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.
Jong Yeob Kim, Keum Hwa Lee, +12 authors, Gabriele Gamerith.
Cancers (Basel), 2019 Nov 07; 11(11). PMID: 31683809    Free PMC article.
A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed.
Shuncong Wang, Yewei Liu, +4 authors, Yicheng Ni.
Cancers (Basel), 2019 Nov 27; 11(11). PMID: 31766180    Free PMC article.
Review.
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target.
Frank Aboubakar Nana, Marie Vanderputten, Sebahat Ocak.
Cancers (Basel), 2019 Nov 02; 11(11). PMID: 31671774    Free PMC article.
Review.
Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy.
Heikki Vilhonen, Samu Kurki, Tarja Laitinen, Samuli Hirsjärvi.
Medicina (Kaunas), 2019 Nov 21; 55(11). PMID: 31744064    Free PMC article.
A case of non-small cell lung cancer with long-term response after re-challenge with nivolumab.
Keima Ito, Tetsuya Oguri, +9 authors, Akio Niimi.
Respir Med Case Rep, 2020 Jan 01; 29. PMID: 31890556    Free PMC article.
Clinical characteristics of colitis induced by taxane-based chemotherapy.
Ellie Chen, Hamzah Abu-Sbeih, +8 authors, Yinghong Wang.
Ann Gastroenterol, 2020 Jan 02; 33(1). PMID: 31892799    Free PMC article.
U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.
Koji Haratani, Kimio Yonesaka, +15 authors, Kazuhiko Nakagawa.
J Clin Invest, 2019 Oct 30; 130(1). PMID: 31661465    Free PMC article.
Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA.
Xiaohui Zeng, Xiaomin Wan, +4 authors, Chongqing Tan.
BMJ Open, 2019 Dec 14; 9(12). PMID: 31831534    Free PMC article.
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
Youngtae Jeong, Jessica A Hellyer, +8 authors, Maximilian Diehn.
Clin Cancer Res, 2019 Sep 25; 26(1). PMID: 31548347    Free PMC article.
Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Kathrin Gennen, Lukas Käsmann, +9 authors, Farkhad Manapov.
Radiat Oncol, 2020 Jan 04; 15(1). PMID: 31898519    Free PMC article.
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.
Nicolas Jacquelot, Takahiro Yamazaki, +30 authors, Laurence Zitvogel.
Cell Res, 2019 Sep 05; 29(10). PMID: 31481761    Free PMC article.
Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer.
Yu Nakanishi, Takeshi Masuda, +12 authors, Noboru Hattori.
Int J Clin Oncol, 2019 Sep 19; 25(1). PMID: 31531785
Pulmonary function is implicated in the prognosis of metastatic non-small cell lung cancer but not in extended disease small cell lung cancer.
Suk-Young Lee, Yoon Ji Choi, +3 authors, Eun Joo Kang.
J Thorac Dis, 2020 Jan 07; 11(11). PMID: 31903245    Free PMC article.
Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.
Yoshiaki Amino, Satoru Kitazono, +8 authors, Makoto Nishio.
Int J Clin Oncol, 2019 Sep 12; 25(1). PMID: 31506751
[Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors].
Guoqiang Pan, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2019 Dec 26; 22(12). PMID: 31874675    Free PMC article.
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.
Wenxiao Jia, Qianqian Gao, +2 authors, Jinming Yu.
Cancer Biol Med, 2020 Jan 08; 16(4). PMID: 31908886    Free PMC article.
Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis.
Jing Qi, Liming Xu, +2 authors, Lujun Zhao.
Cancer Manag Res, 2020 Jan 11; 11. PMID: 31920386    Free PMC article.
Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies.
Jingli Lu, Jing Yang, +3 authors, Xiaojian Zhang.
Front Pharmacol, 2020 Jan 11; 10. PMID: 31920646    Free PMC article.
Systematic Review.
Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies.
Yu-Tong Chen, Sharvesh Raj Seeruttun, Xiang-Yuan Wu, Zi-Xian Wang.
Front Oncol, 2020 Jan 11; 9. PMID: 31921683    Free PMC article.
Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms.
Gaurav Goyal, Denise Lau, +11 authors, Mayo Clinic Histiocytosis Working Group.
Blood, 2019 Jan 31; 133(14). PMID: 30696619    Free PMC article.
Review.
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.
James Godfrey, Sravya Tumuluru, +9 authors, Justin Kline.
Blood, 2019 Mar 27; 133(21). PMID: 30910787    Free PMC article.
Imaging of tumour response to immunotherapy.
Clarisse Dromain, Catherine Beigelman, +2 authors, Antonia Digklia.
Eur Radiol Exp, 2020 Jan 05; 4(1). PMID: 31900689    Free PMC article.
Systematic Review.
Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer.
Fan Zhang, Di Huang, +13 authors, Yi Hu.
J Cancer, 2020 Jan 17; 11(3). PMID: 31942197    Free PMC article.
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer.
Ryan H Moy, Gustavo Dos Santos Fernandes, +19 authors, Yelena Y Janjigian.
Oncologist, 2019 Oct 02; 25(1). PMID: 31570517    Free PMC article.
Current Status of Immunotherapy for Lung Cancer and Future Perspectives.
Ho Cheol Kim, Chang Min Choi.
Tuberc Respir Dis (Seoul), 2020 Jan 07; 83(1). PMID: 31905428    Free PMC article.
Review.
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
Louise A Koopman, Mikkel G Terp, +12 authors, Henrik J Ditzel.
JCI Insight, 2019 Oct 11; 4(21). PMID: 31600169    Free PMC article.
Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer: A systematic review and meta-analysis.
Jian Xie, Zewen Zhang, +4 authors, Yuan Tian.
Medicine (Baltimore), 2019 Dec 20; 98(50). PMID: 31852114    Free PMC article.
Systematic Review.
Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report.
Emanuela Cimpeanu, Jibran Ahmed, +4 authors, Dennis Bloomfield.
World J Clin Cases, 2020 Jan 24; 8(1). PMID: 31970174    Free PMC article.
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors.
Nicholas Gravbrot, Kacy Gilbert-Gard, +4 authors, Srinath Sundararajan.
Antibodies (Basel), 2019 Oct 24; 8(4). PMID: 31640266    Free PMC article.
Review.
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC.
Julia Kargl, Xiaodong Zhu, +15 authors, A McGarry Houghton.
JCI Insight, 2019 Dec 20; 4(24). PMID: 31852845    Free PMC article.
Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vitor F Vasconcellos, Guilherme N Marta, +3 authors, Rachel Riera.
Cochrane Database Syst Rev, 2020 Jan 14; 1. PMID: 31930743    Free PMC article.
Systematic Review.
Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis.
Jiahang Mo, Xiao Hu, +7 authors, Jiequan Liu.
World J Surg Oncol, 2020 Jan 22; 18(1). PMID: 31959178    Free PMC article.
First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.
Thierry Landre, Gaetan Des Guetz, +3 authors, Christos Chouaïd.
J Cancer Res Clin Oncol, 2019 Nov 07; 146(2). PMID: 31686247
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Hayato Kawachi, Motohiro Tamiya, +17 authors, Toru Kumagai.
Invest New Drugs, 2019 Dec 01; 38(1). PMID: 31784866
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Hisao Imai, Satoshi Wasamoto, +15 authors, Kyoichi Kaira.
J Cancer Res Clin Oncol, 2019 Dec 20; 146(2). PMID: 31853661
Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
Steven D Criss, Lauren Palazzo, +4 authors, Chung Yin Kong.
PLoS One, 2020 Jan 30; 15(1). PMID: 31995619    Free PMC article.
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
Wungki Park, Laura Mezquita, +14 authors, Gilberto Lopes.
Br J Cancer, 2019 Nov 26; 122(3). PMID: 31761899    Free PMC article.
Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.
Elisabeth Smolle, Katharina Leithner, Horst Olschewski.
Thorac Cancer, 2019 Dec 05; 11(2). PMID: 31799812    Free PMC article.
Review.
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Alejandro Ruiz-Patiño, Oscar Arrieta, +28 authors, CLICaP.
Thorac Cancer, 2019 Dec 13; 11(2). PMID: 31828967    Free PMC article.
Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Seongho Park, Yoo-Duk Choi, +4 authors, Young-Chul Kim.
Thorac Cancer, 2019 Dec 17; 11(2). PMID: 31841269    Free PMC article.
Combined Atezolizumab and Chemotherapy for a Patient With Double Primary Cancers.
Shinichiro Okauchi, Yuika Sasatani, +2 authors, Hiroaki Satoh.
In Vivo, 2019 Dec 29; 34(1). PMID: 31882503    Free PMC article.
Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer.
Guanghui Gao, Keyi Jia, +7 authors, Caicun Zhou.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010570    Free PMC article.
Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy.
Juan Ruiz-Bañobre, María C Areses-Manrique, +12 authors, Sergio Vázquez.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010585    Free PMC article.
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.
Zhengyang Hu, Ming Li, +3 authors, Qun Wang.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010587    Free PMC article.
Review.
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
Mitsunori Morita, Motohiro Tamiya, +11 authors, Hiromi Tomioka.
BMC Cancer, 2020 Feb 06; 20(1). PMID: 32013910    Free PMC article.
The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases.
Jaleh Fallah, Manmeet S Ahluwalia.
Ann Transl Med, 2020 Feb 06; 7(Suppl 8). PMID: 32016032    Free PMC article.
Paradigm shift in local consolidative therapy for oligometastatic non-small cell lung cancer: a meta-analysis.
Christopher Cao, Adam Chakos, +3 authors, Prunella Blinman.
Ann Transl Med, 2020 Feb 06; 7(Suppl 8). PMID: 32016038    Free PMC article.
EGFR mutations in lung cancer: not all equal in the eyes of the immune system?
Kwun M Fong, Brett G M Hughes, Zarnie Lwin, Ian A Yang.
Ann Transl Med, 2020 Feb 06; 7(Suppl 8). PMID: 32016044    Free PMC article.
The role of immune checkpoint inhibitors (ICI) in the treatment of metastatic non-small cell lung carcinoma in the elderly.
Johan Chan, Ravindran Kanesvaran.
Ann Transl Med, 2020 Feb 06; 7(Suppl 8). PMID: 32016101    Free PMC article.
Beyond PD-L1 Markers for Lung Cancer Immunotherapy.
Kamila Wojas-Krawczyk, Ewa Kalinka, +2 authors, Janusz Milanowski.
Int J Mol Sci, 2019 Apr 21; 20(8). PMID: 31003463    Free PMC article.
Review.
A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer.
Hao Luo, Liang Zhang, +7 authors, Nan Dai.
Invest New Drugs, 2019 Aug 11; 38(1). PMID: 31399906    Free PMC article.
Directing Traffic: How to Effectively Drive T Cells into Tumors.
Annabelle J Anandappa, Catherine J Wu, Patrick A Ott.
Cancer Discov, 2020 Jan 25; 10(2). PMID: 31974169    Free PMC article.
Review.
A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group.
Koji Haratani, Masayuki Takeda, Kazuhiko Nakagawa.
J Thorac Dis, 2020 Feb 08; 11(12). PMID: 32030287    Free PMC article.
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Jianchun Duan, Longgang Cui, +17 authors, Jie Wang.
JAMA Oncol, 2019 Dec 27; 6(3). PMID: 31876895    Free PMC article.
Systematic Review.
Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.
Suresh S Ramalingam, Suzanne E Dahlberg, +12 authors, Joan H Schiller.
J Clin Oncol, 2019 Jul 31; 37(26). PMID: 31361535    Free PMC article.
Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?
Pascale Tomasini, Laurent Greillier.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038906    Free PMC article.
Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?
Laura Le, Ritchell van Dams, Percy Lee.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038907    Free PMC article.
Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer.
Maria Jove, Noelia Vilariño, Ernest Nadal.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038916    Free PMC article.
KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit.
Amy Lauren Cummings, Edward B Garon.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038925    Free PMC article.
Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next.
Tao Jiang, Caicun Zhou, Jie Hu, Yuanlin Song.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038935    Free PMC article.
Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity.
Daan van den Broek, T Jeroen N Hiltermann, +15 authors, Marjolijn J L Ligtenberg.
Front Oncol, 2020 Feb 11; 9. PMID: 32039011    Free PMC article.
Review.
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Minglei Zhuo, Yanfang Guan, +35 authors, Jun Zhao.
Clin Cancer Res, 2019 Nov 07; 26(4). PMID: 31694833    Free PMC article.
Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis.
Leitao Sun, Leyin Zhang, +7 authors, Shengliang Qiu.
Sci Rep, 2020 Feb 09; 10(1). PMID: 32034198    Free PMC article.
Systematic Review.
A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.
Ashley E Ross, Paula J Hurley, +9 authors, Emmanuel S Antonarakis.
Prostate Cancer Prostatic Dis, 2019 Oct 16; 23(1). PMID: 31611635    Free PMC article.
In Search of the Long-Desired 'Copernican Therapeutic Revolution' in Small-Cell Lung Cancer.
Noemí Reguart, Elba Marin, +2 authors, Cristina Teixido.
Drugs, 2020 Jan 09; 80(3). PMID: 31912414
Review.
Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo.
Wanfu Men, Peiyao Zhu, +6 authors, Shuguang Zhang.
Drug Deliv, 2020 Jan 12; 27(1). PMID: 31924103    Free PMC article.
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Chengdi Wang, Wenliang Qiao, +5 authors, Weimin Li.
J Cell Physiol, 2019 Nov 07; 235(5). PMID: 31693178    Free PMC article.
Systematic Review.
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Edward B Garon, Giorgio Vittorio Scagliotti, +17 authors, Maurice Pérol.
ESMO Open, 2020 Jan 21; 5(1). PMID: 31958290    Free PMC article.
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data.
Lida A Mina, Shannon Lim, Shakeela W Bahadur, Abdul T Firoz.
Breast Cancer (Dove Med Press), 2020 Feb 27; 11. PMID: 32099454    Free PMC article.
Review.
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.
Federico Nichetti, Francesca Ligorio, +11 authors, Marina Chiara Garassino.
Cancers (Basel), 2019 Dec 29; 12(1). PMID: 31881699    Free PMC article.
Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy.
Julijan Kabiljo, Felix Harpain, Sebastian Carotta, Michael Bergmann.
Cancers (Basel), 2020 Jan 08; 12(1). PMID: 31905723    Free PMC article.
Review.
Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Ryuya Edahiro, Masaki Kanazu, +11 authors, Motohiro Tamiya.
PLoS One, 2019 Aug 01; 14(7). PMID: 31365588    Free PMC article.
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity.
Shumei Kato, Ryosuke Okamura, +11 authors, Razelle Kurzrock.
Oncoimmunology, 2020 Mar 03; 9(1). PMID: 32117584    Free PMC article.
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study.
Reut Hadash-Bengad, Emma Hajaj, +9 authors, Jonatan E Cohen.
Front Oncol, 2020 Mar 03; 10. PMID: 32117727    Free PMC article.
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy.
Erik Henke, Rajender Nandigama, Süleyman Ergün.
Front Mol Biosci, 2020 Mar 03; 6. PMID: 32118030    Free PMC article.
Review.
Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Misato Jono, Yuhei Kinehara, +10 authors, Isao Tachibana.
Intern Med, 2019 Nov 02; 59(4). PMID: 31666468    Free PMC article.
Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Ning Wan, Tian-Tian Zhang, +7 authors, Jian Li.
Cancer Med, 2020 Jan 17; 9(5). PMID: 31945265    Free PMC article.
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.
Ami N Shah, Lisa Flaum, +7 authors, William Gradishar.
J Immunother Cancer, 2020 Feb 16; 8(1). PMID: 32060053    Free PMC article.
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Ryoji Kato, Hidetoshi Hayashi, +19 authors, Kazuhiko Nakagawa.
J Immunother Cancer, 2020 Feb 19; 8(1). PMID: 32066647    Free PMC article.
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Katsuyuki Hotta, Nobukazu Fujimoto.
J Immunother Cancer, 2020 Feb 27; 8(1). PMID: 32098830    Free PMC article.
Review.
Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum.
Heidi A Hamann, Elizabeth S Ver Hoeve, +2 authors, Jamie S Ostroff.
J Thorac Oncol, 2018 May 26; 13(8). PMID: 29800746    Free PMC article.
Review.
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Stephen J Bagley, Suzanna Talento, +4 authors, Anil Vachani.
J Natl Compr Canc Netw, 2019 May 16; 17(5). PMID: 31085759    Free PMC article.
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
Frank B Cortazar, Zoe A Kibbelaar, +28 authors, David E Leaf.
J Am Soc Nephrol, 2020 Jan 04; 31(2). PMID: 31896554    Free PMC article.
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.
Jessica J Lin, Emily Chin, +8 authors, Alice T Shaw.
J Thorac Oncol, 2018 Sep 12; 14(1). PMID: 30205166    Free PMC article.
Comparing the effects of different cell death programs in tumor progression and immunotherapy.
Michelle N Messmer, Annelise G Snyder, Andrew Oberst.
Cell Death Differ, 2018 Oct 21; 26(1). PMID: 30341424    Free PMC article.
Review.
Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
Sarah B Goldberg, Roy S Herbst.
Cancer, 2018 Nov 02; 124(24). PMID: 30383887    Free PMC article.
To the edge of cell death and back.
Yi-Nan Gong, Jeremy Chase Crawford, Bradlee L Heckmann, Douglas R Green.
FEBS J, 2018 Dec 07; 286(3). PMID: 30506628    Free PMC article.
Review.
C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer.
Daniel C McFarland, Kelly Shaffer, +2 authors, Andrew H Miller.
Cancer, 2018 Dec 07; 125(5). PMID: 30521079    Free PMC article.
Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors.
Francesco Bertolini.
Br J Cancer, 2018 Dec 13; 120(2). PMID: 30538261    Free PMC article.
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Steven D Criss, Meghan J Mooradian, +5 authors, Chung Yin Kong.
JAMA Oncol, 2018 Dec 14; 5(3). PMID: 30543349    Free PMC article.
Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells.
Hugh S Gannon, Tao Zou, +13 authors, Matthew Meyerson.
Nat Commun, 2018 Dec 24; 9(1). PMID: 30575730    Free PMC article.
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Yixin Zhou, Chen Chen, +10 authors, Li Zhang.
J Immunother Cancer, 2018 Dec 24; 6(1). PMID: 30577837    Free PMC article.
Systematic Review.
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Hiroshi Soda, Daiki Ogawara, +9 authors, Hiroshi Mukae.
Thorac Cancer, 2018 Dec 26; 10(2). PMID: 30582295    Free PMC article.
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Roman M Chabanon, Gareth Muirhead, +20 authors, Sophie Postel-Vinay.
J Clin Invest, 2018 Dec 28; 129(3). PMID: 30589644    Free PMC article.
Highly Cited.
Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy.
Xiaosheng Wu, Yanli Li, +11 authors, Haidong Dong.
Heliyon, 2019 Jan 04; 4(12). PMID: 30603685    Free PMC article.
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.
Christopher J D Wallis, Mohit Butaney, +5 authors, Zachary Klaassen.
JAMA Oncol, 2019 Jan 04; 5(4). PMID: 30605213    Free PMC article.
Highly Cited. Systematic Review.
Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies.
Christopher C Frohne, Ernesto M Llano, +2 authors, Jason J Luke.
J Immunother Cancer, 2019 Jan 08; 7(1). PMID: 30612589    Free PMC article.
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era.
Carminia M Della Corte, Carl M Gay, Lauren A Byers.
Cancer, 2019 Jan 09; 125(4). PMID: 30620399    Free PMC article.
Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.
Gabriel A Brooks, Andrea M Austin, +3 authors, Deborah Schrag.
JAMA Netw Open, 2019 Jan 16; 1(6). PMID: 30646220    Free PMC article.
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Aida Karachi, Changlin Yang, +7 authors, Maryam Rahman.
Neuro Oncol, 2019 Jan 23; 21(6). PMID: 30668768    Free PMC article.
Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).
Georg Maschmeyer, Julien De Greef, +7 authors, European Conference on Infections in Leukemia (ECIL).
Leukemia, 2019 Feb 01; 33(4). PMID: 30700842    Free PMC article.
Highly Cited. Review.
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
Matthew J Bott, Stephen C Yang, +11 authors, Stephen R Broderick.
J Thorac Cardiovasc Surg, 2019 Feb 06; 158(1). PMID: 30718052    Free PMC article.
Artificial intelligence in cancer imaging: Clinical challenges and applications.
Wenya Linda Bi, Ahmed Hosny, +16 authors, Hugo J W L Aerts.
CA Cancer J Clin, 2019 Feb 06; 69(2). PMID: 30720861    Free PMC article.
Highly Cited. Review.
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Rui Chen, Xiaoming Hou, Liping Yang, Da Zhao.
Thorac Cancer, 2019 Feb 09; 10(4). PMID: 30734504    Free PMC article.
Systematic Review.
Lung cancer stigma and depression: Validation of the Lung Cancer Stigma Inventory.
Jamie S Ostroff, Kristen E Riley, +3 authors, Heidi A Hamann.
Psychooncology, 2019 Feb 20; 28(5). PMID: 30779396    Free PMC article.
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Norimichi Akiyama, Masato Karayama, +17 authors, Takafumi Suda.
Invest New Drugs, 2019 Feb 23; 37(3). PMID: 30790149
Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
Ilke Tunali, Jhanelle E Gray, +5 authors, Matthew B Schabath.
Lung Cancer, 2019 Feb 25; 129. PMID: 30797495    Free PMC article.
Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.
Shun Lu, Yongfeng Yu, Yi Yang.
Oncologist, 2019 Mar 02; 24(Suppl 1). PMID: 30819828    Free PMC article.
Review.
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Liliang Xia, Yuanyong Liu, Ying Wang.
Oncologist, 2019 Mar 02; 24(Suppl 1). PMID: 30819829    Free PMC article.
Review.
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Deborah B Doroshow, Miguel F Sanmamed, +6 authors, Roy S Herbst.
Clin Cancer Res, 2019 Mar 03; 25(15). PMID: 30824587    Free PMC article.
Highly Cited. Review.
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment.
Hari Menon, Rishab Ramapriyan, +13 authors, James W Welsh.
Front Immunol, 2019 Mar 05; 10. PMID: 30828330    Free PMC article.
Highly Cited. Review.
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.
S Trebeschi, S G Drago, +15 authors, H J W L Aerts.
Ann Oncol, 2019 Mar 22; 30(6). PMID: 30895304    Free PMC article.
Highly Cited.
Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye.
Tom van den Ende, Stef P Menting, +2 authors, Hanneke W M van Laarhoven.
Oncologist, 2019 Mar 25; 24(4). PMID: 30902915    Free PMC article.
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Meghan E Sise, Harish Seethapathy, Kerry L Reynolds.
Oncologist, 2019 Mar 25; 24(6). PMID: 30902916    Free PMC article.
Review.
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Andrea Botticelli, Massimiliano Salati, +11 authors, Paolo Marchetti.
J Transl Med, 2019 Mar 29; 17(1). PMID: 30917841    Free PMC article.
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies.
Dongxu Wang, Jianzhen Lin, +7 authors, Haitao Zhao.
J Hematol Oncol, 2019 Apr 25; 12(1). PMID: 31014381    Free PMC article.
Review.
Emerging therapies for non-small cell lung cancer.
Chao Zhang, Natasha B Leighl, Yi-Long Wu, Wen-Zhao Zhong.
J Hematol Oncol, 2019 Apr 27; 12(1). PMID: 31023335    Free PMC article.
Highly Cited. Review.
Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer.
Edoardo Isnaldi, Anna Garuti, +16 authors, Alberto Ballestrero.
J Transl Med, 2019 May 01; 17(1). PMID: 31036005    Free PMC article.
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Yixin Zhou, Zuan Lin, +4 authors, Li Zhang.
J Immunother Cancer, 2019 May 06; 7(1). PMID: 31053172    Free PMC article.
Modeling Cancer with Flies and Fish.
Ross L Cagan, Leonard I Zon, Richard M White.
Dev Cell, 2019 May 08; 49(3). PMID: 31063751    Free PMC article.
Review.
Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
Fabio Conforti, Laura Pala, +9 authors, Aron Goldhirsch.
J Natl Cancer Inst, 2019 May 21; 111(8). PMID: 31106827    Free PMC article.
Systematic Review.
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
Bishal Gyawali, Spencer Phillips Hey, Aaron S Kesselheim.
JAMA Intern Med, 2019 May 29; 179(7). PMID: 31135808    Free PMC article.
Highly Cited. Review.
Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma.
Candice C Poon, Paul M K Gordon, +7 authors, John J P Kelly.
Oncotarget, 2019 May 30; 10(33). PMID: 31139325    Free PMC article.
Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.
Kazuki Takada, Mototsugu Shimokawa, +8 authors, Masaki Mori.
PLoS One, 2019 Jun 05; 14(6). PMID: 31163080    Free PMC article.
The importance of molecular characterization in lung cancer.
Gilberto de Castro Junior, Guilherme Harada, Evandro Sobroza de Mello.
J Bras Pneumol, 2019 Jun 06; 45(3). PMID: 31166375    Free PMC article.
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Diego Signorelli, Patrizia Giannatempo, +11 authors, Immune-Oncology YOUNG Group.
Biomed Res Int, 2019 Jun 11; 2019. PMID: 31179334    Free PMC article.
Review.
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.
Mohammad Jafarnejad, Chang Gong, +6 authors, Aleksander S Popel.
AAPS J, 2019 Jun 27; 21(5). PMID: 31236847    Free PMC article.
Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
Yaru Tian, Xiaoyang Zhai, +2 authors, Jinming Yu.
J Hematol Oncol, 2019 Jun 30; 12(1). PMID: 31253167    Free PMC article.
Review.
Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.
Maria Saigi, Juan J Alburquerque-Bejar, Montse Sanchez-Cespedes.
Oncogene, 2019 Jun 30; 38(31). PMID: 31253869
Review.
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.
Hirotoshi Iihara, Mototsugu Shimokawa, +10 authors, Yasushi Ohno.
BMJ Open, 2019 Jul 07; 9(7). PMID: 31278102    Free PMC article.
Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study.
C Kappel, M Rushton, +5 authors, S Dent.
Curr Oncol, 2019 Jul 10; 26(3). PMID: 31285675    Free PMC article.
The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma.
Shaodong Hong, Dongbing Liu, +27 authors, Li Zhang.
Nat Commun, 2019 Jul 18; 10(1). PMID: 31311932    Free PMC article.
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance.
Xiaoguang Li, Zhida Liu, +8 authors, Yang-Xin Fu.
Nat Commun, 2019 Jul 22; 10(1). PMID: 31324798    Free PMC article.
Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Jingsi Dong, Daxing Zhu, +7 authors, Qinghua Zhou.
PLoS One, 2019 Jul 28; 14(7). PMID: 31348821    Free PMC article.
Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors.
Shih-Chieh Chang, Yi-Chun Lai, +5 authors, Jiun-I Lai.
Transl Oncol, 2019 Aug 12; 12(11). PMID: 31401335    Free PMC article.
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Yoshihiko Sakata, Kodai Kawamura, +9 authors, Takuro Sakagami.
Thorac Cancer, 2019 Nov 05; 10(12). PMID: 31679185    Free PMC article.
Pembrolizumab microgravity crystallization experimentation.
Paul Reichert, Winifred Prosise, +11 authors, Corey Strickland.
NPJ Microgravity, 2019 Dec 10; 5. PMID: 31815178    Free PMC article.
Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.
Sanna Iivanainen, Jussi P Koivunen.
Int J Mol Sci, 2020 Jan 19; 21(2). PMID: 31952311    Free PMC article.
Review.
Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Nobuhiko Kanaya, Shinji Kuroda, +13 authors, Toshiyoshi Fujiwara.
Mol Ther, 2020 Jan 29; 28(3). PMID: 31991110    Free PMC article.
Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.
Nagla Abdel Karim, Karen Kelly.
Oncologist, 2019 Mar 28; 24(9). PMID: 30914465    Free PMC article.
Review.
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Alberto Pavan, Lorenzo Calvetti, +7 authors, Laura Bonanno.
Oncologist, 2019 Apr 25; 24(8). PMID: 31015312    Free PMC article.
Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
Yusuke Chihara, Akihiro Yoshimura, +12 authors, Koichi Takayama.
Oncologist, 2019 May 02; 24(8). PMID: 31040252    Free PMC article.
Beyond DNA repair: the novel immunological potential of PARP inhibitors.
Roman M Chabanon, Jean-Charles Soria, Christopher J Lord, Sophie Postel-Vinay.
Mol Cell Oncol, 2019 May 28; 6(2). PMID: 31131303    Free PMC article.
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Salma K Jabbour, Abigail T Berman, +9 authors, Jyoti Malhotra.
JAMA Oncol, 2020 Feb 23; 6(6). PMID: 32077891    Free PMC article.
Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer.
Shiqiang Wang, Chongling Hu, Fei Xie, Yanhui Liu.
Onco Targets Ther, 2020 Mar 12; 13. PMID: 32158220    Free PMC article.
Review.
Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study.
Zhichao Tian, Yonghao Yang, +5 authors, Jiaqiang Wang.
Cancer Manag Res, 2020 Mar 12; 12. PMID: 32158266    Free PMC article.
Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies.
Sonam Puri, Michael Shafique.
Drugs Context, 2020 Mar 12; 9. PMID: 32158484    Free PMC article.
Review.
The MyoD family inhibitor domain-containing protein enhances the chemoresistance of cancer stem cells in the epithelial state by increasing β-catenin activity.
Chao-Ju Chen, Chih-Jen Yang, +2 authors, Yu-Peng Liu.
Oncogene, 2020 Jan 09; 39(11). PMID: 31911618
Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.
Kenneth L Kehl, Michael J Hassett, Deborah Schrag.
Cancer Med, 2020 Jan 29; 9(6). PMID: 31989786    Free PMC article.
[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)].
Caicun Zhou, Jie Wang, +13 authors, Shukui Qin.
Zhongguo Fei Ai Za Zhi, 2020 Feb 26; 23(2). PMID: 32093450    Free PMC article.
[Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer].
Hanfei Guo, Rilan Bai, Jiuwei Cui.
Zhongguo Fei Ai Za Zhi, 2020 Feb 26; 23(2). PMID: 32093454    Free PMC article.
Review.
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Isamu Okamoto, Hiroshi Nokihara, +16 authors, Kazuhiko Nakagawa.
JAMA Oncol, 2020 Mar 13; 6(5). PMID: 32163097    Free PMC article.
The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Yuan Tian, Zewen Zhang, +7 authors, Yi Zhao.
Front Oncol, 2020 Mar 18; 10. PMID: 32181158    Free PMC article.
Systematic Review.
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
Mari Aso, Yukihiro Toi, +15 authors, Shunichi Sugawara.
Oncologist, 2020 Mar 13; 25(3). PMID: 32162801    Free PMC article.
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy.
Leyre Zubiri, Ian M Allen, +16 authors, Kerry L Reynolds.
Oncologist, 2020 Mar 13; 25(3). PMID: 32162817    Free PMC article.
T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer.
Deqiang Fu, Jichun Wu, +4 authors, Qiuyu Zhang.
Am J Cancer Res, 2020 Mar 21; 10(2). PMID: 32195021    Free PMC article.
PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer.
Huaqiang Zhou, Jiaqing Liu, +5 authors, Li Zhang.
NPJ Precis Oncol, 2020 Mar 21; 4. PMID: 32195359    Free PMC article.
Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.
Jun W Kim, Cesar P Marquez, +13 authors, E Alejandro Sweet-Cordero.
Nat Med, 2019 Nov 09; 25(11). PMID: 31700175    Free PMC article.
Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?
Caterina Vivaldi, Silvia Catanese, +7 authors, Lorenzo Fornaro.
Int J Mol Sci, 2020 Mar 04; 21(5). PMID: 32121290    Free PMC article.
Review.
KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer.
Jose M Pacheco.
Transl Lung Cancer Res, 2020 Mar 25; 9(1). PMID: 32206562    Free PMC article.
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.
Chennianci Zhu, Weihao Zhuang, +2 authors, Wen-Bin Ou.
Transl Lung Cancer Res, 2020 Mar 25; 9(1). PMID: 32206559    Free PMC article.
Review.
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.
Thomas S Uldrick, Priscila H Gonçalves, +19 authors, Cancer Immunotherapy Trials Network (CITN)-12 Study Team.
JAMA Oncol, 2019 Jun 04; 5(9). PMID: 31154457    Free PMC article.
Highly Cited.
Metadherin enhances vulnerability of cancer cells to ferroptosis.
Jianling Bi, Shujie Yang, +8 authors, Xiangbing Meng.
Cell Death Dis, 2019 Sep 19; 10(10). PMID: 31527591    Free PMC article.
Management of Brain Metastases in Non-Small-Cell Lung Cancer.
Vinicius Ernani, Thomas E Stinchcombe.
J Oncol Pract, 2019 Nov 13; 15(11). PMID: 31715122    Free PMC article.
Review.
Initial Experience after Transition to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer Treated in a Rural Healthcare Region.
Carsten Nieder, Anne Reigstad, +2 authors, Terje Tollåli.
Cureus, 2020 Mar 27; 12(2). PMID: 32211263    Free PMC article.
Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.
Wenhan Yang, Peng Men, +2 authors, Qiuhua Luo.
Front Oncol, 2020 Mar 27; 10. PMID: 32211312    Free PMC article.
Systematic Review.
Metabolic enzymes expressed by cancer cells impact the immune infiltrate.
Gautier Stoll, Margerie Kremer, +7 authors, Guido Kroemer.
Oncoimmunology, 2019 May 10; 8(6). PMID: 31069148    Free PMC article.
Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies.
Shazia K Nakhoda, Anthony J Olszanski.
Pharmaceut Med, 2020 Mar 12; 34(2). PMID: 32157638    Free PMC article.
Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy.
Wei Mu, Ilke Tunali, +3 authors, Robert J Gillies.
Eur J Nucl Med Mol Imaging, 2019 Dec 07; 47(5). PMID: 31807885    Free PMC article.
Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020.
A Elkrief, P Joubert, +3 authors, B Routy.
Curr Oncol, 2020 Mar 29; 27(1). PMID: 32218661    Free PMC article.
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.
Peter T Harrison, Simon Vyse, Paul H Huang.
Semin Cancer Biol, 2019 Sep 29; 61. PMID: 31562956    Free PMC article.
Review.
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Tomoya Fukui, Shinji Hosotani, +13 authors, Katsuhiko Naoki.
Thorac Cancer, 2020 Feb 15; 11(4). PMID: 32057187    Free PMC article.
Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
Hongge Liang, Yan Xu, +3 authors, Jing Zhao.
Thorac Cancer, 2020 Mar 05; 11(4). PMID: 32129934    Free PMC article.
Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer.
Chengdi Wang, Wenliang Qiao, +5 authors, Weimin Li.
Cancer Med, 2019 Jun 06; 8(8). PMID: 31165589    Free PMC article.
Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer.
Oscar Arrieta, Alejandro Aviles-Salas, +9 authors, Laura-Alejandra Ramirez-Tirado.
Cancer Med, 2020 Feb 12; 9(7). PMID: 32043750    Free PMC article.
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.
Chongxian Pan, Hongtao Liu, +4 authors, Lei Zheng.
J Hematol Oncol, 2020 Apr 05; 13(1). PMID: 32245497    Free PMC article.
Review.
A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
Yasuhiro Kato, Yusuke Okuma, +4 authors, Tatsuru Okamura.
Cancer Chemother Pharmacol, 2019 Apr 18; 84(2). PMID: 30993397    Free PMC article.
Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer.
Lei Guo, Peng Song, +6 authors, Wenbin Li.
J Immunother, 2019 May 31; 42(6). PMID: 31145232    Free PMC article.
Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
Luigi Della Gravara, Ciro Battiloro, +4 authors, Danilo Rocco.
Lung Cancer Manag, 2020 Apr 08; 9(1). PMID: 32256708    Free PMC article.
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
B Ricciuti, M Brambilla, +9 authors, R Chiari.
Clin Transl Oncol, 2019 Jul 25; 22(5). PMID: 31332704
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
D Isla, J de Castro, +5 authors, J M Trigo.
Clin Transl Oncol, 2019 Aug 02; 22(5). PMID: 31368078
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.
Thierry Berghmans, Valérie Durieux, Lizza E L Hendriks, Anne-Marie Dingemans.
Front Med (Lausanne), 2020 Apr 09; 7. PMID: 32266275    Free PMC article.
Systematic Review.
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Thaiz Rivera Vargas, Lionel Apetoh.
Front Immunol, 2019 Jun 14; 10. PMID: 31191545    Free PMC article.
Review.
Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.
Jaimin J Patel, Dylan A Levy, +2 authors, Terry A Day.
Head Neck, 2019 Nov 26; 42(4). PMID: 31762164    Free PMC article.
Systematic Review.
Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Fausto Petrelli, Diego Signorelli, +12 authors, Gianluca Tomasello.
Cancers (Basel), 2020 Mar 04; 12(3). PMID: 32120803    Free PMC article.
Review.
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents.
Paola Ciciola, Priscilla Cascetta, +2 authors, Roberto Bianco.
J Clin Med, 2020 Mar 07; 9(3). PMID: 32138216    Free PMC article.
Review.
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.
Andrea Cavazzoni, Graziana Digiacomo, +12 authors, Andrea Ardizzoni.
Cancers (Basel), 2020 Mar 18; 12(3). PMID: 32178474    Free PMC article.
Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity.
Barbara Seliger.
Front Immunol, 2019 Jun 11; 10. PMID: 31178856    Free PMC article.
Review.
Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer.
Takeshi Masuda, Kazunori Fujitaka, +19 authors, Noboru Hattori.
J Thorac Dis, 2020 Apr 11; 12(3). PMID: 32274176    Free PMC article.
Immunotherapy, Inflammation and Colorectal Cancer.
Charles Robert Lichtenstern, Rachael Katie Ngu, Shabnam Shalapour, Michael Karin.
Cells, 2020 Mar 08; 9(3). PMID: 32143413    Free PMC article.
Review.
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
Raju K Vaddepally, Prakash Kharel, +2 authors, Abhinav B Chandra.
Cancers (Basel), 2020 Apr 05; 12(3). PMID: 32245016    Free PMC article.
Review.
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Naiyer A Rizvi, Byoung Chul Cho, +28 authors, MYSTIC Investigators.
JAMA Oncol, 2020 Apr 10; 6(5). PMID: 32271377    Free PMC article.
Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis.
Rui Cao, Jie-Tao Ma, +6 authors, Cheng-Bo Han.
Cancer Med, 2019 Jul 13; 8(11). PMID: 31297962    Free PMC article.
In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening.
Cheng-Guang Wu, Francesca Chiovaro, +2 authors, Alex Soltermann.
J Transl Med, 2020 Apr 12; 18(1). PMID: 32276643    Free PMC article.
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
Giuseppe Lo Russo, Francesco Facchinetti, +2 authors, Roberto Ferrara.
Curr Oncol Rep, 2020 Apr 17; 22(5). PMID: 32296957
Review.
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer.
Jaanika Narits, Hannes Tamm, Jana Jaal.
Clin Transl Radiat Oncol, 2020 Apr 18; 22. PMID: 32300664    Free PMC article.
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer.
James W Opzoomer, Dominika Sosnowska, +2 authors, James N Arnold.
Front Immunol, 2019 Aug 06; 10. PMID: 31379850    Free PMC article.
Review.
External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different.
Andrew Dodson, Suzanne Parry, +7 authors, Erik Thunnissen.
J Pathol Clin Res, 2019 Dec 19; 6(2). PMID: 31849189    Free PMC article.
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.
Paul K Paik, Rachel K Kim, +12 authors, Charles M Rudin.
Clin Cancer Res, 2020 Jan 11; 26(8). PMID: 31919132    Free PMC article.
Immunotherapy Combined with Chemotherapy as a Promising Therapy for a EGFR Exon 19 Deletion with MET Amplification Patient with Non-Small-Cell Lung Cancer: A Case Report.
QingTao Ni, Chi Pan, ShengBin Dai, Peng Wang.
Onco Targets Ther, 2020 Apr 21; 13. PMID: 32308434    Free PMC article.
A Multimodal Approach to Evaluate for Cardiac Metastasis in a Case of Non-Small Cell Lung Cancer.
Nadeem Bilani, Leah Elson, +4 authors, Evan Alley.
Case Rep Oncol, 2020 Apr 21; 13(1). PMID: 32308579    Free PMC article.
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.
Jie Liu, Chengming Li, +2 authors, Xue Meng.
Oncoimmunology, 2020 Apr 22; 9(1). PMID: 32313723    Free PMC article.
Systematic Review.
5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming.
Philip J Kuehl, Carmen S Tellez, +12 authors, Steven A Belinsky.
Br J Cancer, 2020 Feb 28; 122(8). PMID: 32103148    Free PMC article.
Acquired Resistance to Immune Checkpoint Inhibitors.
Adam J Schoenfeld, Matthew D Hellmann.
Cancer Cell, 2020 Apr 15; 37(4). PMID: 32289269    Free PMC article.
Review.
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Jonas Kuon, Adriane Hommertgen, +8 authors, Michael Thomas.
Trials, 2020 Apr 24; 21(1). PMID: 32321565    Free PMC article.
Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a two-year period using continuous bronchoscopy: A case report.
Kei Morikawa, Hirotaka Kida, +3 authors, Masamichi Mineshita.
Thorac Cancer, 2020 Mar 07; 11(5). PMID: 32142590    Free PMC article.
Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
Kazuaki Harada, Makoto Ogasawara, +11 authors, Takuto Miyagishima.
Thorac Cancer, 2020 Mar 18; 11(5). PMID: 32181993    Free PMC article.
Review.
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Laurent Mhanna, Nicolas Guibert, Julie Milia, Julien Mazieres.
Curr Treat Options Oncol, 2019 Jun 07; 20(7). PMID: 31172347    Free PMC article.
Review.
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index.
Daphne Day, Christina Guo, +11 authors, Philippe L Bedard.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337489    Free PMC article.
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Stefano Kim, Bruno Buecher, +21 authors, Christophe Borg.
BMC Cancer, 2020 Apr 27; 20(1). PMID: 32334548    Free PMC article.
Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
Chih-Hsi Scott Kuo, Chin-Chou Wang, +8 authors, Cheng-Ta Yang.
Thorac Cancer, 2019 Apr 06; 10(5). PMID: 30950239    Free PMC article.
Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
Dwight H Owen, Terence M Williams, +7 authors, Gregory A Otterson.
Lung Cancer, 2019 Jul 20; 134. PMID: 31319977    Free PMC article.
Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.
Mao Lin, Haihua Luo, +4 authors, Yong Jiang.
J Clin Invest, 2020 Feb 07; 130(5). PMID: 32027620    Free PMC article.
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.
A Pavan, I Attili, +3 authors, L Bonanno.
J Immunother Cancer, 2019 Aug 07; 7(1). PMID: 31383005    Free PMC article.
Review.
Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
Arsen Osipov, May Tun Saung, Lei Zheng, Adrian G Murphy.
J Immunother Cancer, 2019 Aug 24; 7(1). PMID: 31439034    Free PMC article.
Review.
Current issues and perspectives in PD-1 blockade cancer immunotherapy.
Kenji Chamoto, Ryusuke Hatae, Tasuku Honjo.
Int J Clin Oncol, 2020 Jan 05; 25(5). PMID: 31900651    Free PMC article.
Review.
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
Carminia M Della Corte, Triparna Sen, +21 authors, Lauren A Byers.
J Thorac Oncol, 2020 Feb 19; 15(5). PMID: 32068166    Free PMC article.
COVID-19: the use of immunotherapy in metastatic lung cancer.
Alexander P Davis, Michael Boyer, Jenny H Lee, Steven C Kao.
Immunotherapy, 2020 May 01; 12(8). PMID: 32349579    Free PMC article.
Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review.
Xiangyu Su, Jing Zhang, +2 authors, Cailian Wang.
Onco Targets Ther, 2020 May 06; 13. PMID: 32368090    Free PMC article.
Immuno-oncology-the new paradigm of lung cancer treatment.
D E Dawe, C H Harlos, R A Juergens.
Curr Oncol, 2020 May 06; 27(Suppl 2). PMID: 32368177    Free PMC article.
Review.
Biomarkers of immune checkpoint inhibitor efficacy in cancer.
D E Meyers, S Banerji.
Curr Oncol, 2020 May 06; 27(Suppl 2). PMID: 32368180    Free PMC article.
Review.
Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer.
Lingdi Zhao, Baozhen Ma, +3 authors, Quanli Gao.
Front Oncol, 2020 May 07; 10. PMID: 32373522    Free PMC article.
Immunotherapeutic approaches for small-cell lung cancer.
Wade T Iams, Jason Porter, Leora Horn.
Nat Rev Clin Oncol, 2020 Feb 15; 17(5). PMID: 32055013    Free PMC article.
Review.
5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients.
Min Zhang, Yibo Fan, +8 authors, Xiujuan Qu.
Front Oncol, 2020 May 12; 10. PMID: 32391259    Free PMC article.
Keynote 42: Pembrolizumab, PD-L1, and where to draw the line.
James Isaacs, Jeffrey Clarke, Neal Ready.
Ann Transl Med, 2020 May 13; 8(7). PMID: 32395561    Free PMC article.
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers.
Kazuo Okadome, Yoshifumi Baba, +15 authors, Hideo Baba.
Br J Cancer, 2020 Mar 27; 122(10). PMID: 32210369    Free PMC article.
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
Charu Aggarwal, Jeffrey C Thompson, +18 authors, Erica L Carpenter.
Clin Cancer Res, 2020 Feb 28; 26(10). PMID: 32102950    Free PMC article.
Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non-Small Cell Lung Cancer.
Chen Lin, Xun Shi, +6 authors, Ying Jin.
Front Oncol, 2020 May 16; 10. PMID: 32411590    Free PMC article.
Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition.
Madhawa de Silva, Malinda Itchins, Nick Pavlakis.
Ann Transl Med, 2020 May 16; 8(8). PMID: 32411778    Free PMC article.
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.
Jhanelle E Gray, Andreas Saltos, +14 authors, Amer A Beg.
Clin Cancer Res, 2019 Aug 15; 25(22). PMID: 31409616    Free PMC article.
Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia.
Ilaria Maggio, Lisa Manuzzi, +3 authors, Davide Campana.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235636    Free PMC article.
Review.
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors.
Stephan Rheinheimer, Claus-Peter Heussel, +13 authors, Petros Christopoulos.
Cancers (Basel), 2020 Apr 29; 12(4). PMID: 32340408    Free PMC article.
Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis.
Hengrui Liang, Guo Lin, +15 authors, Wenhua Liang.
Transl Lung Cancer Res, 2020 May 19; 9(2). PMID: 32420059    Free PMC article.
Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
Camille Travert, Pascale Tomasini, Fabrice Barlesi.
Transl Lung Cancer Res, 2020 May 19; 9(2). PMID: 32420082    Free PMC article.
Anti-PDL1 effect in squamous non-small cell lung cancer.
Mohamed Rahouma, Massimo Baudo, +2 authors, Nasser Altorki.
Transl Lung Cancer Res, 2020 May 19; 9(2). PMID: 32420083    Free PMC article.
The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer.
Maria Lucia Reale, Emmanuele De Luca, Massimo Di Maio.
Transl Lung Cancer Res, 2020 May 19; 9(2). PMID: 32420084    Free PMC article.
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.
Pengfei Cui, Di Huang, +9 authors, Yi Hu.
Ther Adv Med Oncol, 2020 May 20; 12. PMID: 32426052    Free PMC article.
Toxicity of Carlina Oxide-A Natural Polyacetylene from the Carlina acaulis Roots-In Vitro and In Vivo Study.
Artur Wnorowski, Sylwia Wnorowska, +10 authors, Maciej Strzemski.
Toxins (Basel), 2020 Apr 15; 12(4). PMID: 32283677    Free PMC article.
Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.
Daniel P Feldmann, Joshua Heyza, +2 authors, Olivia M Merkel.
Molecules, 2020 Apr 30; 25(8). PMID: 32344513    Free PMC article.
The emerging role of epigenetic therapeutics in immuno-oncology.
Michael J Topper, Michelle Vaz, +2 authors, Stephen B Baylin.
Nat Rev Clin Oncol, 2019 Sep 25; 17(2). PMID: 31548600    Free PMC article.
Review.
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
Praveen Vikas, Nicholas Borcherding, Adithya Chennamadhavuni, Rohan Garje.
Front Oncol, 2020 May 28; 10. PMID: 32457830    Free PMC article.
Review.
The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.
Run-Cong Nie, Chong-Bang Zhao, +6 authors, Yuan-Fang Li.
Biomed Res Int, 2020 May 29; 2020. PMID: 32461994    Free PMC article.
Systematic Review.
Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation.
Hann-Hsiang Chao, Ilias V Karagounis, +4 authors, Amit Maity.
Oncogene, 2020 Apr 27; 39(22). PMID: 32335582    Free PMC article.
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yunfang Yu, Dongqiang Zeng, +8 authors, Herui Yao.
JAMA Netw Open, 2019 Jul 11; 2(7). PMID: 31290993    Free PMC article.
Highly Cited.
Clinical characteristics and prognosis of pulmonary large cell carcinoma: A population-based retrospective study using SEER data.
Liu Xiaochuan, Yu Jiangyong, +2 authors, Li Lin.
Thorac Cancer, 2020 Apr 18; 11(6). PMID: 32301286    Free PMC article.
Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma.
Maria Togo, Takehiko Yokobori, +8 authors, Tetsunari Oyama.
Br J Cancer, 2020 Apr 03; 122(11). PMID: 32238919    Free PMC article.
Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.
A T Freeman, M Lesperance, +8 authors, D Ksienski.
Curr Oncol, 2020 Jun 04; 27(2). PMID: 32489249    Free PMC article.
Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer.
B Melosky, S Banerji, +5 authors, P Cheema.
Curr Oncol, 2020 Jun 04; 27(2). PMID: 32489263    Free PMC article.
How to read a published clinical trial: A practical guide for clinicians.
Mohamad B Sonbol, Belal M Firwana, Talal Hilal, Mohammad Hassan Murad.
Avicenna J Med, 2019 Apr 01; 10(2). PMID: 32500045    Free PMC article.
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
P Garrido, E Conde, +7 authors, F López-Ríos.
Clin Transl Oncol, 2019 Oct 11; 22(7). PMID: 31598903    Free PMC article.
The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis.
S-Y Zheng, H-J Cui, +8 authors, X Jiang.
Clin Transl Oncol, 2019 Nov 22; 22(7). PMID: 31748961    Free PMC article.
Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer.
Till Wallrabenstein, Jessica Del Rio, Arnoud J Templeton, Martin Buess.
PLoS One, 2020 May 30; 15(5). PMID: 32470017    Free PMC article.
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial.
Claudio Vernieri, Monica Ganzinelli, +16 authors, Marina C Garassino.
ESMO Open, 2020 May 30; 5(3). PMID: 32467099    Free PMC article.
PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake.
Jian-Ye Zhang, Yan-Yan Yan, +2 authors, Li-Wu Fu.
Front Pharmacol, 2020 Jun 13; 11. PMID: 32528284    Free PMC article.
Review.
Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells.
Tamio Okimoto, Hitoshi Kotani, +5 authors, Mamoru Harada.
Cancer Sci, 2020 Apr 02; 111(6). PMID: 32232903    Free PMC article.
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Shintaro Kanda, Yuichiro Ohe, +6 authors, Tomohide Tamura.
Cancer Sci, 2020 Apr 12; 111(6). PMID: 32277531    Free PMC article.
Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma.
Kengo Kuriyama, Tamami Higuchi, +13 authors, Hiroshi Saeki.
Cancer Sci, 2020 Apr 18; 111(6). PMID: 32302443    Free PMC article.
Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer.
Magdalena Zaborowska-Szmit, Maciej Krzakowski, Dariusz M Kowalski, Sebastian Szmit.
J Clin Med, 2020 May 01; 9(5). PMID: 32349387    Free PMC article.
Review.
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient.
Giovanni Rossi, Alessandro Russo, +13 authors, Carlo Genova.
Cancers (Basel), 2020 May 06; 12(5). PMID: 32365882    Free PMC article.
Review.
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer.
Joshua M Walker, Annah S Rolig, +6 authors, William L Redmond.
J Immunother Cancer, 2020 May 28; 8(1). PMID: 32457127    Free PMC article.
Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Michael S Leapman, Carolyn J Presley, +5 authors, Cary P Gross.
JAMA Netw Open, 2020 Jun 09; 3(6). PMID: 32511721    Free PMC article.
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Oscar Arrieta, Feliciano Barrón, +12 authors, Rafael Rosell.
JAMA Oncol, 2020 Apr 10; 6(6). PMID: 32271354    Free PMC article.
Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay.
Diego A Lema, Ewa Jankowska-Gan, +2 authors, Ticiana Leal.
J Immunother Cancer, 2020 Jun 13; 8(1). PMID: 32527929    Free PMC article.
From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses.
Julijan Kabiljo, Johannes Laengle, Michael Bergmann.
Cell Death Discov, 2020 Jun 17; 6. PMID: 32542113    Free PMC article.
Review.
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
Matthew D Hellmann, Barzin Y Nabet, +32 authors, Maximilian Diehn.
Clin Cancer Res, 2020 Feb 13; 26(12). PMID: 32046999    Free PMC article.
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
Keisuke Onoi, Yusuke Chihara, +6 authors, Koichi Takayama.
J Clin Med, 2020 May 10; 9(5). PMID: 32384677    Free PMC article.
Review.
The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report.
Mengmeng Lyu, Yang Shen, +3 authors, Jinhua Wang.
Onco Targets Ther, 2020 Jun 18; 13. PMID: 32547077    Free PMC article.
Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice.
Yu Chen, Yanqing Pei, +3 authors, Xiangjiao Meng.
Front Immunol, 2020 Jun 18; 11. PMID: 32547566    Free PMC article.
Review.
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology.
Stefano Frega, Alessandro Dal Maso, +4 authors, Laura Evangelista.
Cancers (Basel), 2020 May 28; 12(5). PMID: 32455666    Free PMC article.
Review.
Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer.
Tamjeed Ahmed, Thomas Lycan, +8 authors, W Jeffrey Petty.
Clin Lung Cancer, 2020 Feb 25; 21(4). PMID: 32089478    Free PMC article.
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Da Hyun Kang, Sung Soo Jung, +8 authors, Jeong Eun Lee.
BMC Cancer, 2020 Jun 20; 20(1). PMID: 32552717    Free PMC article.
Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer.
Daniel C Liebler, Timothy R Holzer, +6 authors, Aaron M Gruver.
Sci Rep, 2020 Jun 20; 10(1). PMID: 32555523    Free PMC article.
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.
Rui Jin, Jing Zhao, +4 authors, Yang Xia.
Ther Adv Med Oncol, 2020 Jun 23; 12. PMID: 32565926    Free PMC article.
Review.
Proposals for managing patients with thoracic malignancies during COVID-19 pandemic.
N Girard, L Greillier, +14 authors, French-Language Society of Pulmonology SPLF French-language Oncology Group.
Respir Med Res, 2020 Jun 22; 78. PMID: 32563968    Free PMC article.
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Michael Offin, Robin Guo, +18 authors, Alexander Drilon.
JCO Precis Oncol, 2019 Jun 14; 3. PMID: 31192313    Free PMC article.
Tumor-Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma.
Zongyi Yang, Jia Feng, +9 authors, Ming Shi.
Hepatology, 2019 Sep 04; 71(5). PMID: 31479523    Free PMC article.
Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
Etienne Giroux Leprieur, Zofia Hélias-Rodzewicz, +10 authors, Jean-François Emile.
J Immunother Cancer, 2020 Jun 26; 8(1). PMID: 32581058    Free PMC article.
Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up.
Ramona Dadu, Theresa E Rodgers, +6 authors, Hussein Tawbi.
J Immunother Cancer, 2020 Jun 26; 8(1). PMID: 32581059    Free PMC article.
Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects.
Deepam Pushpam, Vikas Garg, Sandip Ganguly, Bivas Biswas.
Onco Targets Ther, 2020 Jul 02; 13. PMID: 32606731    Free PMC article.
Review.
Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review.
Na Li, Huanrui Zheng, +3 authors, Maobai Liu.
Cancer Manag Res, 2020 Jul 02; 12. PMID: 32606944    Free PMC article.
Review.
Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients.
Si-Yang Liu, Hao Sun, +10 authors, Yi-Long Wu.
Biomark Res, 2020 Jul 02; 8. PMID: 32607238    Free PMC article.
Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival.
Eniko Barczi, Tamas Nagy, +6 authors, Veronika Müller.
Thorac Cancer, 2020 May 14; 11(7). PMID: 32401433    Free PMC article.
Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Shingo Kitagawa, Taiki Hakozaki, Rui Kitadai, Yukio Hosomi.
Thorac Cancer, 2020 May 19; 11(7). PMID: 32421224    Free PMC article.
Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Minjiang Chen, Qiang Li, +5 authors, Mengzhao Wang.
Thorac Cancer, 2020 May 30; 11(7). PMID: 32468726    Free PMC article.
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Xue Bai, De-Hua Wu, +11 authors, Zhong-Yi Dong.
J Immunother Cancer, 2020 Jul 02; 8(1). PMID: 32606052    Free PMC article.
Role of DNA repair defects in predicting immunotherapy response.
Jing Zhang, David J H Shih, Shiaw-Yih Lin.
Biomark Res, 2020 Jul 03; 8. PMID: 32612833    Free PMC article.
Review.
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
Jesus Vera Aguilera, Jonas Paludo, +10 authors, Yiyi Yan.
Melanoma Res, 2020 May 15; 30(4). PMID: 32404734    Free PMC article.
Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma.
Won-Mook Choi, Jonggi Choi, +10 authors, Kang Mo Kim.
Hepatol Commun, 2020 Jul 07; 4(7). PMID: 32626838    Free PMC article.
Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers.
Antti Tikkanen, Sanna Iivanainen, Jussi P Koivunen.
J Cancer Res Clin Oncol, 2020 Apr 20; 146(8). PMID: 32306129    Free PMC article.
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
Ying-Nai Wang, Heng-Huan Lee, +2 authors, Mien-Chie Hung.
J Biomed Sci, 2020 Jul 06; 27(1). PMID: 32620165    Free PMC article.
Review.
Implementing a multidisciplinary approach for older adults with Cancer: geriatric oncology in practice.
Carolyn J Presley, Jessica L Krok-Schoen, +6 authors, Ashley E Rosko.
BMC Geriatr, 2020 Jul 08; 20(1). PMID: 32631254    Free PMC article.
Comprehensive investigation of T and B cell receptor repertoires in an MC38 tumor model following murine anti‑PD‑1 administration.
Lu Zhang, I-Ming Wang, +3 authors, Brian Long.
Mol Med Rep, 2020 May 30; 22(2). PMID: 32468004    Free PMC article.
Bronchoscopic tissue yield for advanced molecular testing: are we getting enough?
Pattraporn Tajarernmuang, Linda Ofiara, Stéphane Beaudoin, Anne V Gonzalez.
J Thorac Dis, 2020 Jul 10; 12(6). PMID: 32642252    Free PMC article.
Review.
Novel genetic variants of KIR3DL2 and PVR involved in immunoregulatory interactions are associated with non-small cell lung cancer survival.
Yufeng Wu, Sen Yang, +8 authors, Qingyi Wei.
Am J Cancer Res, 2020 Jul 10; 10(6). PMID: 32642289    Free PMC article.
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
Willemijn S M E Theelen, Heike M U Peulen, +9 authors, Paul Baas.
JAMA Oncol, 2019 Jul 12; 5(9). PMID: 31294749    Free PMC article.
Highly Cited.
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.
Joshua M Bauml, Rosemarie Mick, +11 authors, Corey J Langer.
JAMA Oncol, 2019 Jul 12; 5(9). PMID: 31294762    Free PMC article.
Highly Cited.
Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
Fiona Mienko, Balazs Halmos, Haiying Cheng.
Ann Transl Med, 2020 Jul 11; 8(12). PMID: 32647703    Free PMC article.
Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now.
Mark G Kris, Corinne Faivre-Finn, +4 authors, Stephen Swisher.
Am Soc Clin Oncol Educ Book, 2020 Apr 17; 40. PMID: 32298162    Free PMC article.
Review.
Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy.
Lukas Käsmann, Chukwuka Eze, +6 authors, Farkhad Manapov.
Radiat Oncol, 2020 Jul 11; 15(1). PMID: 32646443    Free PMC article.
Review.
[Study on enhancing the killing activity of chemotherapy drugs by PD-1 inhibitor on Raji cell line].
R Zhang, X Li, +4 authors, Q Deng.
Zhonghua Xue Ye Xue Za Zhi, 2020 Feb 07; 41(1). PMID: 32023760    Free PMC article.
The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial.
Andrea Botticelli, Silvia Mezi, +16 authors, Paolo Marchetti.
Vaccines (Basel), 2020 Apr 25; 8(2). PMID: 32326034    Free PMC article.
Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer.
Mark Kriegsmann, Christian Haag, +18 authors, Katharina Kriegsmann.
Cancers (Basel), 2020 Jun 21; 12(6). PMID: 32560475    Free PMC article.
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.
Stefanie Schatz, Markus Falk, +12 authors, Lukas C Heukamp.
Cancers (Basel), 2020 Jul 01; 12(6). PMID: 32599951    Free PMC article.
Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review.
Philippe Rochigneux, Alejandro J Garcia, +3 authors, Edward B Garon.
Front Immunol, 2020 Jul 17; 11. PMID: 32670271    Free PMC article.
Systematic Review.
Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy.
Fan Zhang, Di Huang, +14 authors, Yi Hu.
Ther Adv Med Oncol, 2020 Jul 17; 12. PMID: 32670420    Free PMC article.
Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies.
Robert J Walsh, Ross A Soo.
Ther Adv Med Oncol, 2020 Jul 17; 12. PMID: 32670423    Free PMC article.
Review.
Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
Kyle G Mitchell, Marcelo V Negrao, +14 authors, Boris Sepesi.
Ann Thorac Surg, 2019 Sep 25; 109(2). PMID: 31550464    Free PMC article.
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system.
Arsela Prelaj, Claudia Proto, +14 authors, Mattia Boeri.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676324    Free PMC article.
The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung.
Yoshinobu Ichiki, Takashi Fukuyama, Kozo Nakanishi.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676343    Free PMC article.
First-line immune-chemotherapy combination for squamous NSCLC is already a reality.
Lizza E L Hendriks, Jessica Menis, Jordi Remon.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676345    Free PMC article.
Pembrolizumab-the "KEY" to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC).
Amulya Yellala, Apar Kishor Ganti.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676346    Free PMC article.
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Lucia Nogova, Christian Mattonet, +28 authors, Jürgen Wolf.
Cancer Med, 2020 May 22; 9(14). PMID: 32436621    Free PMC article.
Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.
Hao Xu, Songshan Chai, +4 authors, Nanxiang Xiong.
CNS Neurosci Ther, 2020 Jul 18; 26(8). PMID: 32678519    Free PMC article.
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study.
Dominique Arpin, Marie-Christine Charpentier, +23 authors, Diane Damotte.
Ther Adv Med Oncol, 2020 Jul 21; 12. PMID: 32684990    Free PMC article.
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
J Nicholas Bodor, Yanis Boumber, Hossein Borghaei.
Cancer, 2019 Nov 07; 126(2). PMID: 31691957    Free PMC article.
Review.
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Andrea Botticelli, Alessio Cirillo, +18 authors, Paolo Marchetti.
Vaccines (Basel), 2020 May 02; 8(2). PMID: 32353934    Free PMC article.
Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer.
Tal Flieswasser, Jinthe Van Loenhout, +7 authors, Julie Jacobs.
Cells, 2020 Jun 21; 9(6). PMID: 32560232    Free PMC article.
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Sarah B Goldberg, Kurt A Schalper, +21 authors, Harriet M Kluger.
Lancet Oncol, 2020 Apr 07; 21(5). PMID: 32251621    Free PMC article.
Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer.
Yuichi Ozawa, Takeya Sugimoto, +4 authors, Kuninobu Kanai.
BMJ Open, 2020 Jul 24; 10(7). PMID: 32699133    Free PMC article.
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Cai Zhang, Yuxia Liu.
Front Immunol, 2020 Jul 28; 11. PMID: 32714324    Free PMC article.
Review.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, +35 authors, O Gautschi.
Ann Oncol, 2019 May 28; 30(8). PMID: 31125062    Free PMC article.
Highly Cited.
Multidisciplinary Approach of Immune Checkpoint Inhibitor-Related Pneumonitis: A Key to Address Knowledge and Management Gaps.
Maurice Pérol.
J Thorac Oncol, 2020 Jul 29; 15(8). PMID: 32718532    Free PMC article.
Immunotherapy - new perspective in lung cancer.
Fillipe Dantas Pinheiro, Adriano Fernandes Teixeira, +3 authors, Fabrício Freire de Melo.
World J Clin Oncol, 2020 Jul 31; 11(5). PMID: 32728528    Free PMC article.
Review.
The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis.
Rupesh Kotecha, Joseph M Kim, +10 authors, Manmeet S Ahluwalia.
Neuro Oncol, 2019 Feb 24; 21(8). PMID: 30796838    Free PMC article.
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
Martin Reck, Thomas Wehler, +16 authors, Mark A Socinski.
J Clin Oncol, 2020 May 28; 38(22). PMID: 32459597    Free PMC article.
Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.
Swapnil Rajurkar, Isa Mambetsariev, +4 authors, Ravi Salgia.
J Clin Med, 2020 Jun 19; 9(6). PMID: 32549358    Free PMC article.
Review.
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Yu Chen, Min Gao, +2 authors, Xiangjiao Meng.
J Hematol Oncol, 2020 Jul 30; 13(1). PMID: 32723363    Free PMC article.
Review.
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial).
Francesco Gelsomino, Giuseppe Lamberti, +15 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2020 Aug 01; 12. PMID: 32733604    Free PMC article.
Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
Kaili Yang, Jiarui Li, +2 authors, Lin Zhao.
Front Oncol, 2020 Aug 01; 10. PMID: 32733805    Free PMC article.
Systematic Review.
Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer.
Ji Eun Park, Jang Hyuck Lee, +13 authors, Jae Yong Park.
J Cancer, 2020 Aug 04; 11(18). PMID: 32742497    Free PMC article.
Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report.
Ping Chen, Min Yu, +5 authors, Shuang Zhang.
World J Clin Cases, 2020 Aug 04; 8(13). PMID: 32742998    Free PMC article.
Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study.
Junjie Zhen, Lei Wen, +13 authors, Cheng Zhou.
Radiat Oncol, 2020 Aug 02; 15(1). PMID: 32736566    Free PMC article.
Value of TTF-1 expression in non-squamous non-small-cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure.
Akira Takeuchi, Tetsuya Oguri, +15 authors, Akio Niimi.
Mol Clin Oncol, 2020 Aug 06; 13(3). PMID: 32754323    Free PMC article.
Combination of Juzentaihoto and chemotherapy improves the prognosis of patients with postoperative recurrence of non-small cell lung cancer.
Hideki Kawai, Yoshitaro Saito.
Mol Clin Oncol, 2020 Aug 06; 13(3). PMID: 32754327    Free PMC article.
Concurrent Hospice Care and Cancer-Directed Treatment for Advanced Lung Cancer and Receipt of Aggressive Care at the End of Life in the Veteran's Health Administration.
Carolyn J Presley, Ling Han, +9 authors, Cary P Gross.
J Palliat Med, 2020 Mar 03; 23(8). PMID: 32119800    Free PMC article.
Association of CD8 T cell apoptosis and EGFR mutation in non-small lung cancer patients.
Chao Zhao, Chunxia Su, Xuefei Li, Caicun Zhou.
Thorac Cancer, 2020 Jun 06; 11(8). PMID: 32500560    Free PMC article.
Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions.
Satoshi Tobita, Yuhei Kinehara, +10 authors, Isao Tachibana.
Thorac Cancer, 2020 Jun 23; 11(8). PMID: 32567218    Free PMC article.
Spondylodiscitis and spinal epidural abscess related to long-term placement of an airway stent for malignant central airway obstruction.
Kohei Shikano, Daisuke Ishii, +8 authors, Koichiro Tatsumi.
Thorac Cancer, 2020 Jun 25; 11(8). PMID: 32579282    Free PMC article.
Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.
Anna Passarelli, Michele Aieta, Alessandro Sgambato, Cesare Gridelli.
Front Immunol, 2020 Aug 08; 11. PMID: 32760402    Free PMC article.
Review.
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context.
Sneha Gullapalli, Jordi Remon, Lizza E L Hendriks, Gilberto Lopes.
Onco Targets Ther, 2020 Aug 09; 13. PMID: 32764980    Free PMC article.
Review.
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver.
So Yeon Kim, Balazs Halmos.
Lung Cancer Manag, 2020 Aug 11; 9(3). PMID: 32774467    Free PMC article.
Review.
Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
Tingting Liu, Bo Jin, +4 authors, Guang Li.
Ther Adv Med Oncol, 2020 Aug 11; 12. PMID: 32774474    Free PMC article.
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China.
Yanhui Chen, Yating Wang, +5 authors, Henghui Zhang.
Exp Hematol Oncol, 2020 Aug 11; 9. PMID: 32775040    Free PMC article.
Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events.
Sandra M Herrmann, Mark A Perazella.
Kidney Int Rep, 2020 Aug 11; 5(8). PMID: 32775813    Free PMC article.
Review.
Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors.
Magalie Dosset, Elodie Lauret-Marie Joseph, Thaiz Rivera Vargas, Lionel Apetoh.
Cells, 2020 Jul 28; 9(7). PMID: 32707692    Free PMC article.
Review.
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.
Rong Tang, Jin Xu, +6 authors, Si Shi.
J Hematol Oncol, 2020 Aug 12; 13(1). PMID: 32778143    Free PMC article.
Review.
Current management of RET rearranged non-small cell lung cancer.
Thomas E Stinchcombe.
Ther Adv Med Oncol, 2020 Aug 13; 12. PMID: 32782485    Free PMC article.
Review.
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm.
Giuseppe Luigi Banna, Ornella Cantale, +4 authors, Alfredo Addeo.
Oncol Rev, 2020 Aug 13; 14(2). PMID: 32782728    Free PMC article.
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Joao V Alessi, Biagio Ricciuti, +12 authors, Mark Awad.
J Immunother Cancer, 2020 Aug 06; 8(2). PMID: 32753547    Free PMC article.
Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Fang Yang, Svetomir N Markovic, +10 authors, Yucai Wang.
JAMA Netw Open, 2020 Aug 09; 3(8). PMID: 32766800    Free PMC article.
Systematic Review.
A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications.
Matthew C Knox, Jie Ni, +4 authors, Yong Li.
Front Immunol, 2020 Aug 15; 11. PMID: 32793238    Free PMC article.
Review.
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
Qingyang Lei, Dan Wang, +2 authors, Yi Zhang.
Front Cell Dev Biol, 2020 Aug 15; 8. PMID: 32793604    Free PMC article.
Review.
Medical management of brain metastases.
Adam Lauko, Yasmeen Rauf, Manmeet S Ahluwalia.
Neurooncol Adv, 2020 Aug 15; 2(1). PMID: 32793881    Free PMC article.
Review.
Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons.
Elisa Aquilanti, Priscilla K Brastianos.
Neurosurgery, 2020 Apr 18; 87(3). PMID: 32302389    Free PMC article.
Review.
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.
Yuanyuan Zhang, Zemin Zhang.
Cell Mol Immunol, 2020 Jul 03; 17(8). PMID: 32612154    Free PMC article.
Review.
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Haiping Jiang, Yulong Zheng, +12 authors, Nong Xu.
BMC Cancer, 2020 Aug 17; 20(1). PMID: 32795349    Free PMC article.
A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies.
Jialin Qu, Li Wang, +5 authors, Xiaochun Zhang.
Cancer Manag Res, 2020 Aug 18; 12. PMID: 32801888    Free PMC article.
Review.
Targeting phosphatidylserine for Cancer therapy: prospects and challenges.
Wenguang Chang, Hongge Fa, Dandan Xiao, Jianxun Wang.
Theranostics, 2020 Aug 18; 10(20). PMID: 32802188    Free PMC article.
Review.
Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
Jiyun Lee, Jong-Mu Sun, +3 authors, Myung-Ju Ahn.
J Thorac Dis, 2020 Aug 18; 12(7). PMID: 32802459    Free PMC article.
Review.
Intratumoral Immunotherapy for Early-stage Solid Tumors.
Wan Xing Hong, Sarah Haebe, +4 authors, Ronald Levy.
Clin Cancer Res, 2020 Feb 20; 26(13). PMID: 32071116    Free PMC article.
Review.
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Tejas Patil, Rao Mushtaq, +10 authors, Robert C Doebele.
Clin Lung Cancer, 2019 Dec 21; 21(3). PMID: 31859066    Free PMC article.
Immunotherapy in Prostate Cancer.
Emily K Fay, Julie N Graff.
Cancers (Basel), 2020 Jul 08; 12(7). PMID: 32630247    Free PMC article.
Review.
Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Koichi Ando, Yasunari Kishino, +6 authors, Hironori Sagara.
Cancers (Basel), 2020 Jul 19; 12(7). PMID: 32679702    Free PMC article.
Review.
Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?
Nagio Takigawa, Nobuaki Ochi, +7 authors, Hiromichi Yamane.
Cancers (Basel), 2020 Jul 28; 12(7). PMID: 32708291    Free PMC article.
Review.
The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer.
Joshua T Burgess, Maddison Rose, +7 authors, Emma Bolderson.
Front Oncol, 2020 Aug 28; 10. PMID: 32850380    Free PMC article.
Review.
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.
Vishal Navani, Moira C Graves, Nikola A Bowden, Andre Van Der Westhuizen.
Br J Clin Pharmacol, 2020 May 10; 86(9). PMID: 32384184    Free PMC article.
Review.
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Farastuk Bozorgmehr, Inn Chung, +6 authors, Stefan Rieken.
BMC Cancer, 2020 Aug 28; 20(1). PMID: 32842974    Free PMC article.
Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries.
Claire M Lanier, Ryan Hughes, +14 authors, Michael D Chan.
Neurooncol Pract, 2019 Sep 27; 6(5). PMID: 31555455    Free PMC article.
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors.
Rilan Bai, Zheng Lv, Dongsheng Xu, Jiuwei Cui.
Biomark Res, 2020 Aug 31; 8. PMID: 32864131    Free PMC article.
Review.
[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
Di Zhang, Jiaqi Huang, +2 authors, Qisen Guo.
Zhongguo Fei Ai Za Zhi, 2019 Jun 15; 22(6). PMID: 31196371    Free PMC article.
Review.
[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
Sixuan Wu, Chunhong Hu, +2 authors, Ping Liu.
Zhongguo Fei Ai Za Zhi, 2019 Jul 19; 22(7). PMID: 31315783    Free PMC article.
Review.
[Immunotherapy in Epidermal Growth Factor Receptor-mutant 
Non-small Cell Lung Cancer].
Xin Wang, Diansheng Zhong.
Zhongguo Fei Ai Za Zhi, 2019 Aug 28; 22(8). PMID: 31451147    Free PMC article.
Review.
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab.
Romain-David Seban, Jean-Baptiste Assié, +10 authors, Laurence Champion.
Cancers (Basel), 2020 Aug 14; 12(8). PMID: 32785166    Free PMC article.
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
Ana Bocanegra, Ester Blanco, +7 authors, Grazyna Kochan.
Int J Mol Sci, 2020 Aug 23; 21(16). PMID: 32824655    Free PMC article.
Review.
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.
Patrick J Roberts, Vishnu Kumarasamy, Agnieszka K Witkiewicz, Erik S Knudsen.
Mol Cancer Ther, 2020 Jun 18; 19(8). PMID: 32546660    Free PMC article.
Review.
Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy.
Maria Francesca Alvisi, Monica Ganzinelli, +15 authors, Mirko Marabese.
J Clin Med, 2020 Aug 06; 9(8). PMID: 32751518    Free PMC article.
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Jakob M Riedl, Dominik A Barth, +16 authors, Florian Posch.
Cancers (Basel), 2020 Aug 23; 12(8). PMID: 32824580    Free PMC article.
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
Wolfgang M Brueckl, Martin Reck, +10 authors, Eckart Laack.
Clin Med Insights Oncol, 2020 Sep 05; 14. PMID: 32884390    Free PMC article.
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Charles M Rudin, Mark M Awad, +18 authors, KEYNOTE-604 Investigators.
J Clin Oncol, 2020 May 30; 38(21). PMID: 32468956    Free PMC article.
Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer.
Boris Sepesi, Tina Cascone, +2 authors, Xiuning Le.
Surg Oncol Clin N Am, 2020 Sep 05; 29(4). PMID: 32883458    Free PMC article.
Review.
Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
Yu Chen, Yi Li, +13 authors, Chuanben Chen.
Mol Oncol, 2020 Jun 06; 14(9). PMID: 32502294    Free PMC article.
Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.
Alexander Neuwelt, Taha Al-Juhaishi, Eduardo Davila, Bradley Haverkos.
Blood Adv, 2020 Sep 09; 4(17). PMID: 32898250    Free PMC article.
Review.
Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Alejandro Ruiz-Patiño, Feliciano Barrón, +19 authors, CLICaP.
Thorac Cancer, 2020 Jul 25; 11(9). PMID: 32705787    Free PMC article.
Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.
Xinru Chen, Zhonghan Zhang, +10 authors, Li Zhang.
J Immunother Cancer, 2020 Aug 31; 8(2). PMID: 32863271    Free PMC article.
Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Haiying Ding, Wenxiu Xin, +4 authors, Yuefeng Rao.
PLoS One, 2020 Sep 03; 15(9). PMID: 32877435    Free PMC article.
Systematic Review.
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.
Norah J Shire, Alyssa B Klein, +6 authors, Naiyer A Rizvi.
PLoS One, 2020 Sep 04; 15(9). PMID: 32881920    Free PMC article.
A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer.
Elizabeth J Cathcart-Rake, Lindsey R Sangaralingham, +3 authors, Aaron S Mansfield.
Clin Lung Cancer, 2020 May 25; 21(5). PMID: 32446852    Free PMC article.
Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.
Noelia Vilariño, Jordi Bruna, +2 authors, Andreas A Argyriou.
Int J Mol Sci, 2020 Aug 17; 21(16). PMID: 32796758    Free PMC article.
Review.
A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient's Suitability for Immune Checkpoint Inhibition.
Michael Wessolly, Susann Stephan-Falkenau, +12 authors, Fabian D Mairinger.
Cancer Manag Res, 2020 Sep 15; 12. PMID: 32922086    Free PMC article.
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Gernot Wagner, Hannah Karolina Stollenwerk, +3 authors, Josef Singer.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923134    Free PMC article.
Systematic Review.
[First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer].
Xiaoxiao Peng, Qing Zhou.
Zhongguo Fei Ai Za Zhi, 2018 Dec 29; 21(12). PMID: 30591101    Free PMC article.
Review.
Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review.
Lukas Käsmann, Alexander Dietrich, +8 authors, Claus Belka.
Radiat Oncol, 2020 Sep 12; 15(1). PMID: 32912295    Free PMC article.
Review.
Biomarkers of immunotherapy in non-small cell lung cancer.
Lingling Wang, Yue Hu, +2 authors, Xiaochen Wang.
Oncol Lett, 2020 Sep 17; 20(5). PMID: 32934707    Free PMC article.
Review.
Prognostic effects of the expression of inhibitor of DNA-binding family members on patients with lung adenocarcinoma.
Xiaomin Lu, Lili Shao, +4 authors, Zhixiang Zhuang.
Oncol Lett, 2020 Sep 17; 20(5). PMID: 32934711    Free PMC article.
PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature.
Amanda Ramos, Marcela Del Carmen, Oladapo Yeku.
Case Rep Oncol Med, 2020 Sep 17; 2020. PMID: 32934857    Free PMC article.
Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis.
Boris Shulgin, Yuri Kosinsky, +8 authors, Gabriel Helmlinger.
Oncoimmunology, 2020 Sep 17; 9(1). PMID: 32934874    Free PMC article.
Review.
Supplementation of l-arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy.
Yusuke Satoh, Hitoshi Kotani, +3 authors, Mamoru Harada.
Cancer Sci, 2020 May 20; 111(7). PMID: 32426941    Free PMC article.
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
Xiaoyang Zhai, Jian Zhang, +4 authors, Hui Zhu.
Cancer Biol Med, 2020 Sep 19; 17(3). PMID: 32944393    Free PMC article.
Review.
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives.
Sabine Wessels, Thomas Muley, +17 authors, Marc A Schneider.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953480    Free PMC article.
Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.
Young Kwang Chae, Won Bin Kim, +11 authors, Pedro Viveiros.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953481    Free PMC article.
Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors.
Sangtian Liu, Fei Zhou, +16 authors, Caicun Zhou.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953484    Free PMC article.
A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians.
Siyu Peng, Ariel Fangting Ying, Bee Choo Tai, Ross Andrew Soo.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953491    Free PMC article.
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
Jiaqi Liang, Ming Li, +7 authors, Lijie Tan.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953506    Free PMC article.
Genetic and microenvironmental differences in non-smoking lung adenocarcinoma patients compared with smoking patients.
Qihai Sui, Jiaqi Liang, +7 authors, Qun Wang.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953513    Free PMC article.
First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus ça change.
Grace K Dy, Maya Khalil, Edwin Yau.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953530    Free PMC article.
Hormone gene signature guides a novel therapeutic opportunity to improve sensitivity to HER family inhibition in lung cancer.
Zachary A Yochum, Laura P Stabile.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953532    Free PMC article.
Alternative splicing of HER2: a novel mediator of EGFR TKI resistance.
Zachary A Yochum, Liza C Villaruz.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953533    Free PMC article.
Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment.
Yumiko Samejima, Atsuhiko Iuchi, +11 authors, Tomonori Hirashima.
Intern Med, 2020 May 26; 59(16). PMID: 32448839    Free PMC article.
Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases.
Zhou Su, Lin Zhou, Jianxin Xue, You Lu.
Chin J Cancer Res, 2020 Sep 24; 32(4). PMID: 32963458    Free PMC article.
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials.
Antonino Grassadonia, Isabella Sperduti, +11 authors, Nicola Tinari.
J Clin Med, 2018 Dec 14; 7(12). PMID: 30545122    Free PMC article.
The clinical promise of immunotherapy in triple-negative breast cancer.
Praveen Vikas, Nicholas Borcherding, Weizhou Zhang.
Cancer Manag Res, 2018 Dec 24; 10. PMID: 30573992    Free PMC article.
Review.
ASCO 2018 NSCLC highlights-combination therapy is key.
Gabriele Gamerith, Florian Kocher, Jakob Rudzki, Andreas Pircher.
Memo, 2019 Jan 01; 11(4). PMID: 30595752    Free PMC article.
Review.
VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story?
Mariam Alexander, Balazs Halmos.
Ann Transl Med, 2019 Jan 04; 6(23). PMID: 30603634    Free PMC article.
Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer.
Rainer C Miksch, Markus B Schoenberg, +6 authors, Jan G D'Haese.
Cancers (Basel), 2019 Jan 06; 11(1). PMID: 30609853    Free PMC article.
Highly Cited.
Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators.
Minsuk Kwon, Young Joon Choi, +2 authors, Eui-Cheol Shin.
Immune Netw, 2019 Jan 09; 18(6). PMID: 30619631    Free PMC article.
Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?
Mariam Alexander, Jose Galeas, Haiying Cheng.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631537    Free PMC article.
PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer.
Bairavi Shankar, Jarushka Naidoo.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631548    Free PMC article.
Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?
Dwight H Owen, Gregory A Otterson.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631557    Free PMC article.
Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience.
Maiko Takeda, Takahiko Kasai, +13 authors, Shinji Atagi.
Clin Med Insights Oncol, 2019 Jan 24; 13. PMID: 30670923    Free PMC article.
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer.
Tiffany Seto, Danny Sam, Minggui Pan.
Med Sci (Basel), 2019 Jan 27; 7(2). PMID: 30678257    Free PMC article.
Review.
The combination strategies will be ready the right first-line choice for squamous lung cancer patients?
Cesare Gridelli, Francesca Casaluce.
Transl Lung Cancer Res, 2019 Feb 02; 7(Suppl 4). PMID: 30705852    Free PMC article.
Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancer.
Rebecca Yin Tay, Christoph Jakob Ackermann, Raffaele Califano.
Transl Lung Cancer Res, 2019 Feb 02; 7(Suppl 4). PMID: 30705861    Free PMC article.
Immunotherapy in extensive small cell lung cancer.
Vaibhav Verma, Geeti Sharma, Abhijai Singh.
Exp Hematol Oncol, 2019 Feb 12; 8. PMID: 30740266    Free PMC article.
Review.
Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?
Francesco Passiglia, Silvia Novello.
Ann Transl Med, 2019 Feb 12; 6(Suppl 2). PMID: 30740441    Free PMC article.
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer.
Courèche Kaderbhaï, Zoé Tharin, François Ghiringhelli.
Cancers (Basel), 2019 Feb 13; 11(2). PMID: 30744168    Free PMC article.
Review.
VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy.
Juan-Manuel Hernandez-Martinez, Edgar Vergara, +2 authors, Oscar Arrieta.
J Thorac Dis, 2019 Feb 13; 10(12). PMID: 30746169    Free PMC article.
Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
Kaikai Shen, Jinggang Cui, +8 authors, Dang Lin.
J Thorac Dis, 2019 Feb 13; 10(12). PMID: 30746209    Free PMC article.
Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy.
Vineet Govinda Gupta, Ranga Rao Rangaraju, +2 authors, Ruchika Khetrapal.
South Asian J Cancer, 2019 Feb 16; 8(1). PMID: 30766859    Free PMC article.
Efficacy and safety of nivolumab for metastatic biliary tract cancer.
Miaomiao Gou, Yong Zhang, Haiyan Si, Guanghai Dai.
Onco Targets Ther, 2019 Feb 19; 12. PMID: 30774373    Free PMC article.
Turning the corner on therapeutic cancer vaccines.
Robert E Hollingsworth, Kathrin Jansen.
NPJ Vaccines, 2019 Feb 19; 4. PMID: 30774998    Free PMC article.
Highly Cited. Review.
Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.
Hélène Blons, Simon Garinet, Pierre Laurent-Puig, Jean-Baptiste Oudart.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775025    Free PMC article.
Review.
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors.
Gaurav Nayyar, Yaya Chu, Mitchell S Cairo.
Front Oncol, 2019 Feb 26; 9. PMID: 30805309    Free PMC article.
Highly Cited. Review.
Chemotherapy for Lung Cancer in the Era of Personalized Medicine.
Seung Hyeun Lee.
Tuberc Respir Dis (Seoul), 2019 Mar 07; 82(3). PMID: 30841023    Free PMC article.
Review.
Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features.
Michele Porcu, Pushpamali De Silva, +8 authors, Luca Saba.
Cancers (Basel), 2019 Mar 08; 11(3). PMID: 30841554    Free PMC article.
Review.
Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials.
Jie Li, Qi He, +3 authors, Minjie Guan.
Cancer Manag Res, 2019 Mar 14; 11. PMID: 30863172    Free PMC article.
Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment.
Concetta Elisa Onesti, Pierre Frères, Guy Jerusalem.
J Thorac Dis, 2019 Mar 14; 11(1). PMID: 30863564    Free PMC article.
Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report.
Takeshi Azuma, Tohru Sugihara, +4 authors, Haruki Kume.
Oncol Lett, 2019 Mar 19; 17(4). PMID: 30881514    Free PMC article.
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.
Chongkai Wang, Prakash Kulkarni, Ravi Salgia.
Mol Ther Oncolytics, 2019 Apr 13; 13. PMID: 30976658    Free PMC article.
Review.
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer.
Jose M Pacheco, D Ross Camidge, Robert C Doebele, Erin Schenk.
Front Oncol, 2019 Apr 16; 9. PMID: 30984621    Free PMC article.
Highly Cited. Review.
Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review.
Vito Longo, Oronzo Brunetti, +4 authors, Nicola Silvestris.
Cancers (Basel), 2019 Apr 18; 11(4). PMID: 30991686    Free PMC article.
Review.
The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination.
Kenichi Suda.
J Thorac Dis, 2019 Apr 19; 11(Suppl 3). PMID: 30997217    Free PMC article.
KEYNOTE-024: goodbye to chemotherapy?
Rossana Berardi.
J Thorac Dis, 2019 Apr 19; 11(Suppl 3). PMID: 30997239    Free PMC article.
Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key.
Robert Pirker.
Ann Transl Med, 2019 Apr 30; 7(Suppl 1). PMID: 31032327    Free PMC article.
An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.
Muhammad Zubair Afzal, Konstantin H Dragnev, Keisuke Shirai.
Ann Transl Med, 2019 Apr 30; 7(Suppl 1). PMID: 31032332    Free PMC article.
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.
Alfredo Addeo, Giuseppe Luigi Banna, Giulio Metro, Massimo Di Maio.
Front Oncol, 2019 May 07; 9. PMID: 31058078    Free PMC article.
Highly Cited. Systematic Review.
Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer.
Aaron Lisberg, Edward B Garon.
Transl Lung Cancer Res, 2019 May 21; 8(2). PMID: 31106131    Free PMC article.
Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis.
Caiqing Zhang, Shuisheng Zhang, +5 authors, Yuan Tian.
Cancer Manag Res, 2019 May 24; 11. PMID: 31118808    Free PMC article.
Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies.
Ryo Sato, Kosuke Imamura, +13 authors, Takuro Sakagami.
J Clin Med, 2019 May 31; 8(6). PMID: 31146442    Free PMC article.
Definitive concurrent chemoradiotherapy in a patient with stage IV non-small cell lung cancer due to cervical lymph node metastases.
Shigeo Takahashi, Shintaro Tarumi, +6 authors, Toru Shibata.
Int Cancer Conf J, 2019 Jun 01; 7(4). PMID: 31149531    Free PMC article.
Immunotherapy in breast cancer.
Soley Bayraktar, Sameer Batoo, Scott Okuno, Stefan Glück.
J Carcinog, 2019 Jun 05; 18. PMID: 31160888    Free PMC article.
Review.
Diagnostic value of ProGRP for small cell lung cancer in different stages.
Aoran Dong, Jiali Zhang, +2 authors, Xinwei Zhang.
J Thorac Dis, 2019 Jun 11; 11(4). PMID: 31179060    Free PMC article.
MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer.
Anna Grenda, Marcin Nicoś, +8 authors, Janusz Milanowski.
Oncol Lett, 2019 Jun 13; 17(6). PMID: 31186735    Free PMC article.
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.
Pauline du Rusquec, Ombline de Calbiac, +2 authors, Jean Sebastien Frenel.
Cancer Manag Res, 2019 Jun 14; 11. PMID: 31190995    Free PMC article.
Review.
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.
Yoshiyuki Nakamura.
Front Med (Lausanne), 2019 Jun 14; 6. PMID: 31192215    Free PMC article.
Review.
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date.
Jordi Remon, Laura Esteller, Álvaro Taus.
Cancer Manag Res, 2019 Jun 20; 11. PMID: 31213908    Free PMC article.
Review.
Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB).
Fangping Ren, Tian Zhao, Bing Liu, Lei Pan.
Onco Targets Ther, 2019 Jun 27; 12. PMID: 31239702    Free PMC article.
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer.
Frank Weinberg, Shirish Gadgeel.
Lung Cancer (Auckl), 2019 Jun 27; 10. PMID: 31239797    Free PMC article.
Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
Emmanuel Acheampong, Isaac Spencer, +3 authors, Elin Gray.
Cancers (Basel), 2019 Jul 03; 11(7). PMID: 31262041    Free PMC article.
Review.
Possible Biomarkers for Cancer Immunotherapy.
Takehiro Otoshi, Tatsuya Nagano, Motoko Tachihara, Yoshihiro Nishimura.
Cancers (Basel), 2019 Jul 07; 11(7). PMID: 31277279    Free PMC article.
Review.
Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer.
Junji Koyama, Atsushi Horiike, +11 authors, Makoto Nishio.
J Thorac Dis, 2019 Jul 10; 11(5). PMID: 31285885    Free PMC article.
Randomized phase II study of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma.
Sheng-Fa Su, Mei Li, +7 authors, Bing Lu.
Am J Cancer Res, 2019 Jul 10; 9(6). PMID: 31285955    Free PMC article.
Immune-Related Adverse Events: A Case-Based Approach.
Caoilfhionn Connolly, Kalindi Bambhania, Jarushka Naidoo.
Front Oncol, 2019 Jul 12; 9. PMID: 31293970    Free PMC article.
Review.
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab.
Angela Alama, Simona Coco, +12 authors, Francesco Grossi.
J Clin Med, 2019 Jul 13; 8(7). PMID: 31295929    Free PMC article.
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.
Florian Huemer, David Lang, +7 authors, Richard Greil.
J Clin Med, 2019 Jul 13; 8(7). PMID: 31295966    Free PMC article.
A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer.
Ning Wan, Bo Ji, +4 authors, Wenjie Huang.
Onco Targets Ther, 2019 Jul 16; 12. PMID: 31303759    Free PMC article.
Review.
Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer.
Jade H-M Hsu, Peter M-H Chang, +10 authors, Jin-Mei Lai.
Cancers (Basel), 2019 Jul 20; 11(7). PMID: 31319622    Free PMC article.
Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers.
Luigi Pasini, Paola Ulivi.
J Clin Med, 2019 Jul 22; 8(7). PMID: 31323990    Free PMC article.
Review.
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review.
Gabrielle Planes-Laine, Philippe Rochigneux, +4 authors, Anthony Gonçalves.
Cancers (Basel), 2019 Jul 25; 11(7). PMID: 31336685    Free PMC article.
Highly Cited. Review.
Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution.
Nikhil Yegya-Raman, Joseph Aisner, +6 authors, Salma K Jabbour.
Adv Radiat Oncol, 2019 Jul 31; 4(3). PMID: 31360811    Free PMC article.
Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.
Sawsan Rashdan, David E Gerber.
Transl Lung Cancer Res, 2019 Aug 02; 8(3). PMID: 31367533    Free PMC article.
Clinical utility of ramucirumab in non-small-cell lung cancer.
Dipesh Uprety.
Biologics, 2019 Aug 16; 13. PMID: 31413541    Free PMC article.
Comprehensive analysis of differentially expressed long non-coding RNAs in non-small cell lung cancer.
Wenyong Zhou, Tao Liu, +3 authors, Heng Zhao.
Oncol Lett, 2019 Aug 20; 18(2). PMID: 31423174    Free PMC article.
Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report.
Yuri Taniguchi, Momoko Yamamoto, +4 authors, Kazuhiro Usui.
Case Rep Oncol, 2019 Aug 21; 12(2). PMID: 31427953    Free PMC article.
First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
Tingting Liu, Silu Ding, +3 authors, Guang Li.
J Thorac Dis, 2019 Aug 30; 11(7). PMID: 31463119    Free PMC article.
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer.
Zhenbin Qiu, Zihao Chen, Chao Zhang, Wenzhao Zhong.
Exp Hematol Oncol, 2019 Aug 30; 8. PMID: 31463163    Free PMC article.
Review.
The role and therapeutic implications of T cells in cancer of the lung.
Samuel C Neeve, Bruce Ws Robinson, Vanessa S Fear.
Clin Transl Immunology, 2019 Sep 06; 8(8). PMID: 31485330    Free PMC article.
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
Jia Li Low, Robert J Walsh, +2 authors, Ross A Soo.
Ther Adv Med Oncol, 2019 Sep 10; 11. PMID: 31497071    Free PMC article.
Review.
The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma.
Gagandeep Brar, Manish A Shah.
Therap Adv Gastroenterol, 2019 Sep 14; 12. PMID: 31516556    Free PMC article.
Review.
A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Motoko Tachihara, Tatsunori Kiriu, +8 authors, Yoshihiro Nishimura.
Cancer Manag Res, 2019 Sep 20; 11. PMID: 31534366    Free PMC article.
Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression.
Antonio Sica, Valentina Guarneri, Alessandra Gennari.
Cell Stress, 2019 Sep 20; 3(9). PMID: 31535085    Free PMC article.
Review.
Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies.
Diana Carolina Sotelo-Rodríguez, Alejandro Ruíz-Patiño, +3 authors, Andrés F Cardona.
Ecancermedicalscience, 2019 Sep 26; 13. PMID: 31552109    Free PMC article.
Review.
The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials.
Yangyang Xu, Bing Wan, +13 authors, written on behalf of AME Lung Cancer Collaborative Group.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555516    Free PMC article.
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.
Akihiro Yoshimura, Tadaaki Yamada, +16 authors, Koichi Takayama.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555518    Free PMC article.
First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?
Francesco Passiglia, Paolo Bironzo, Giorgio V Scagliotti.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555529    Free PMC article.
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
A J Schoenfeld, H Rizvi, +15 authors, M D Hellmann.
Ann Oncol, 2020 Mar 18; 31(5). PMID: 32178965    Free PMC article.
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
Xiaodi Guo, Wendong Li, +2 authors, Qiang Su.
Eur J Clin Pharmacol, 2020 Jun 09; 76(10). PMID: 32507925    Free PMC article.
Systematic Review.
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease.
Masako Yumura, Tatsuya Nagano, Yoshihiro Nishimura.
Molecules, 2020 Sep 05; 25(17). PMID: 32882995    Free PMC article.
Review.
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
Claire F Verschraegen, Guy Jerusalem, +15 authors, James L Gulley.
J Immunother Cancer, 2020 Sep 11; 8(2). PMID: 32907924    Free PMC article.
Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50.
Ou Yamaguchi, Kyoichi Kaira, +7 authors, Ichiei Kuji.
Sci Rep, 2020 Sep 16; 10(1). PMID: 32929123    Free PMC article.
Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
Li Li, Gang Li, +8 authors, Yao-Zhong Wu.
Sci Rep, 2020 Sep 25; 10(1). PMID: 32968172    Free PMC article.
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
Leilei Ai, Jian Chen, +4 authors, Xiaochun Yang.
Drug Des Devel Ther, 2020 Sep 29; 14. PMID: 32982171    Free PMC article.
Review.
Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
Fabio Gomes, Melisa Wong, +4 authors, Andrea Luciani.
Br J Cancer, 2020 Jul 23; 123(6). PMID: 32694695    Free PMC article.
Review.
Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer.
Minkyu Jung, Yanping Yang, +13 authors, Moonsoo M Jin.
Mol Ther Oncolytics, 2020 Oct 01; 18. PMID: 32995483    Free PMC article.
Adult immuno-oncology: using past failures to inform the future.
Maryam Rahman, W Gregory Sawyer, +9 authors, David A Reardon.
Neuro Oncol, 2020 May 12; 22(9). PMID: 32391559    Free PMC article.
PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy.
Yi Qin, Lili Jiang, +11 authors, Meijuan Huang.
Sci Rep, 2020 Oct 02; 10(1). PMID: 32999345    Free PMC article.
Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Xing Li, Lei Wang, +4 authors, Chunxia Su.
Thorac Cancer, 2020 Aug 12; 11(10). PMID: 32779372    Free PMC article.
Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
Tao Zhang, Kunpeng Xu, +8 authors, Luhua Wang.
Thorac Cancer, 2020 Aug 25; 11(10). PMID: 32833338    Free PMC article.
Review.
MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer.
Seigo Katakura, Nobuaki Kobayashi, +13 authors, Takeshi Kaneko.
Thorac Cancer, 2020 Sep 08; 11(10). PMID: 32893980    Free PMC article.
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents.
Mariona Riudavets, Joaquin Mosquera, +9 authors, Margarita Majem.
Front Oncol, 2020 Oct 06; 10. PMID: 33014837    Free PMC article.
ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC.
Yao Chen, Xiaobin Li, +4 authors, Yina Wang.
Front Oncol, 2020 Oct 06; 10. PMID: 33014846    Free PMC article.
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Anne Y Lai, Jessica A Sorrentino, +8 authors, Patrick J Roberts.
J Immunother Cancer, 2020 Oct 03; 8(2). PMID: 33004541    Free PMC article.
Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Shang-Jui Wang, Karishma Khullar, +9 authors, Salma K Jabbour.
J Immunother Cancer, 2020 Oct 07; 8(2). PMID: 33020239    Free PMC article.
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.
J F Gainor, H Rizvi, +25 authors, M D Hellmann.
Ann Oncol, 2020 Feb 19; 31(3). PMID: 32067682    Free PMC article.
Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.
Hirohisa Kano, Eiki Ichihara, +12 authors, Katsuyuki Kiura.
Cancer Sci, 2020 Jul 30; 111(10). PMID: 32726470    Free PMC article.
Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines in vitro and in vivo.
Rui Zhang, Cuicui Lyu, +3 authors, Qi Deng.
Am J Cancer Res, 2020 Oct 13; 10(9). PMID: 33042618    Free PMC article.
Targeting the immune milieu in gastrointestinal cancers.
Fiona Turkes, Justin Mencel, Naureen Starling.
J Gastroenterol, 2020 Aug 05; 55(10). PMID: 32748171    Free PMC article.
Review.
[Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
Qiaoxi Qin, Jiajin Wang, Hong Wang.
Zhongguo Fei Ai Za Zhi, 2020 Aug 06; 23(9). PMID: 32752580    Free PMC article.
Systematic Review.
Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
Zhijie Wang, Jianming Ying, +13 authors, Jie Wang.
JAMA Netw Open, 2020 Oct 06; 3(10). PMID: 33017026    Free PMC article.
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Jeffrey C Thompson, Christiana Davis, +6 authors, Steven M Albelda.
J Immunother Cancer, 2020 Oct 09; 8(2). PMID: 33028693    Free PMC article.
Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer.
Hsiu-Ying Hung, Yen-Han Tseng, +10 authors, Yuh-Min Chen.
PLoS One, 2020 Oct 09; 15(10). PMID: 33031375    Free PMC article.
Non-invasive decision support for NSCLC treatment using PET/CT radiomics.
Wei Mu, Lei Jiang, +10 authors, Matthew B Schabath.
Nat Commun, 2020 Oct 18; 11(1). PMID: 33067442    Free PMC article.
Immune checkpoint inhibitor-related dermatologic adverse events.
Amaris N Geisler, Gregory S Phillips, +5 authors, Mario E Lacouture.
J Am Acad Dermatol, 2020 May 27; 83(5). PMID: 32454097    Free PMC article.
Review.
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Barzin Y Nabet, Mohammad S Esfahani, +29 authors, Maximilian Diehn.
Cell, 2020 Oct 03; 183(2). PMID: 33007267    Free PMC article.
TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice.
Yuki Tanaka, Hiroshi Wada, +9 authors, Teruhiro Utsugi.
Sci Rep, 2020 Oct 16; 10(1). PMID: 33057061    Free PMC article.
Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer.
Atul Batra, Dropen Sheka, Shiying Kong, Winson Y Cheung.
BMC Cancer, 2020 Oct 17; 20(1). PMID: 33059611    Free PMC article.
Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma.
Xiang Zhou, Junlong Wu, Chunguang Duan, Yingjie Liu.
J Immunol Res, 2020 Oct 17; 2020. PMID: 33062726    Free PMC article.
Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Xin Yan, Xuan Tian, Zhiqiang Wu, Weidong Han.
Front Oncol, 2020 Oct 20; 10. PMID: 33072551    Free PMC article.
Systematic Review.
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer.
Chaoyue Su, Hui Wang, +7 authors, Jianye Zhang.
Front Oncol, 2020 Oct 20; 10. PMID: 33072580    Free PMC article.
Review.
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.
James Welsh, Hari Menon, +14 authors, John V Heymach.
J Immunother Cancer, 2020 Oct 15; 8(2). PMID: 33051340    Free PMC article.
Implications of metabolism-driven myeloid dysfunctions in cancer therapy.
Laura Strauss, Valentina Guarneri, Alessandra Gennari, Antonio Sica.
Cell Mol Immunol, 2020 Oct 21; 18(4). PMID: 33077904    Free PMC article.
Review.
Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy.
Jean-David Fumet, Emeric Limagne, Marion Thibaudin, Francois Ghiringhelli.
Cancers (Basel), 2020 Sep 20; 12(9). PMID: 32947882    Free PMC article.
Review.
Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes.
Mark Kriegsmann, Christiane Zgorzelski, +16 authors, Katharina Kriegsmann.
Cancers (Basel), 2020 Sep 25; 12(9). PMID: 32967325    Free PMC article.
Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy.
Florian Huemer, Eckhard Klieser, +13 authors, Lukas Weiss.
J Clin Med, 2020 Sep 02; 9(9). PMID: 32867256    Free PMC article.
Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression.
Weilei Hu, Guosheng Wang, Lonny B Yarmus, Yuan Wan.
Cancers (Basel), 2020 Sep 10; 12(9). PMID: 32899191    Free PMC article.
Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma.
Sophia Heinrich, Darko Castven, Peter R Galle, Jens U Marquardt.
Cancers (Basel), 2020 Sep 10; 12(9). PMID: 32899197    Free PMC article.
Review.
Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Christian Borel, Alain C Jung, Mickaël Burgy.
Cancers (Basel), 2020 Sep 25; 12(9). PMID: 32967162    Free PMC article.
Review.
Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.
Teppei Kamada, Hiroshi Ishiguro, +7 authors, Yutaka Suzuki.
Ann Med Surg (Lond), 2020 Oct 27; 60. PMID: 33101670    Free PMC article.
Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer.
Xiaoyang Zhai, Xuquan Jing, +4 authors, Hui Zhu.
Front Oncol, 2020 Oct 27; 10. PMID: 33102221    Free PMC article.
Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review.
Grzegorz Sławiński, Anna Wrona, +2 authors, Ewa Lewicka.
Int J Mol Sci, 2020 Oct 03; 21(19). PMID: 33003425    Free PMC article.
Review.
Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.
Koji Nagaoka, Masataka Shirai, +8 authors, Kazuhiro Kakimi.
J Immunother Cancer, 2020 Oct 24; 8(2). PMID: 33093158    Free PMC article.
The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
Naoki Furuya, Kentaro Ito, +7 authors, Masamichi Mineshita.
Oncology, 2020 May 29; 98(9). PMID: 32464632    Free PMC article.
FAM64A: A Novel Oncogenic Target of Lung Adenocarcinoma Regulated by Both Strands of miR-99a (miR-99a-5p and miR-99a-3p).
Keiko Mizuno, Kengo Tanigawa, +7 authors, Naohiko Seki.
Cells, 2020 Sep 17; 9(9). PMID: 32932948    Free PMC article.
Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective.
Wen-Jia Shi, Wei Zhao.
Chin Med J (Engl), 2020 Sep 23; 133(20). PMID: 32960841    Free PMC article.
Review.
Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer.
Fang-Fei Qian, Bao-Hui Han.
Chin Med J (Engl), 2020 Sep 25; 133(20). PMID: 32969861    Free PMC article.
Review.
The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: A systematic review and meta-analysis.
Dongmei Xu, Hongmei Liu, +7 authors, Yuan Tian.
Medicine (Baltimore), 2020 Oct 09; 99(41). PMID: 33031304    Free PMC article.
Systematic Review.
Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice.
Hui-Ching Wang, Tsung-Jang Yeh, +2 authors, Shih-Feng Cho.
Int J Mol Sci, 2020 Oct 21; 21(20). PMID: 33076306    Free PMC article.
Review.
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade.
Tomoko Aoki, Masatoshi Kudo, +8 authors, Naoshi Nishida.
Cancers (Basel), 2020 Oct 24; 12(10). PMID: 33092011    Free PMC article.
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.
Zhangfeng Huang, Wenhao Su, +6 authors, Wenjie Jiao.
Front Pharmacol, 2020 Oct 30; 11. PMID: 33117170    Free PMC article.
Review.
Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy.
Maitane Ocáriz-Díez, Mara Cruellas, +10 authors, Eva M Gálvez.
Front Oncol, 2020 Oct 30; 10. PMID: 33117698    Free PMC article.
Review.
Assessment of long non-coding RNA expression reveals novel mediators of the lung tumour immune response.
Adam P Sage, Kevin W Ng, +7 authors, Wan L Lam.
Sci Rep, 2020 Oct 11; 10(1). PMID: 33037279    Free PMC article.
The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors.
Ravindra Pramod Deshpande, Sambad Sharma, Kounosuke Watabe.
Cancers (Basel), 2020 Oct 21; 12(10). PMID: 33076303    Free PMC article.
Review.
Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report.
Ning Yang, Pin-Liang Zhang, Zeng-Jun Liu.
Medicine (Baltimore), 2020 Nov 01; 99(44). PMID: 33126358    Free PMC article.
A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma.
Satoshi Tanaka, Ryo Asakawa, +7 authors, Kiyonobu Ueno.
Respir Med Case Rep, 2020 Nov 03; 31. PMID: 33134073    Free PMC article.
PD-L1 expression in regional lymph nodes and predictable roles in anti-cancer immune responses.
Yoshihiro Komohara, Mamoru Harada, +2 authors, Toshiyuki Nakayama.
J Clin Exp Hematop, 2020 Jul 10; 60(3). PMID: 32641599    Free PMC article.
Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors.
David Bomze, Nethanel Asher, +4 authors, Tomer Meirson.
JAMA Netw Open, 2020 Oct 24; 3(10). PMID: 33095247    Free PMC article.
Revisiting Immunotherapy: A Focus on Prostate Cancer.
Ha-Ram Cha, Joo Hyoung Lee, Selvarangan Ponnazhagan.
Cancer Res, 2020 Feb 19; 80(8). PMID: 32066566    Free PMC article.
Review.
Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.
Idoroenyi Amanam, Isa Mambetsariev, +7 authors, Ravi Salgia.
J Thorac Dis, 2020 Nov 05; 12(9). PMID: 33145085    Free PMC article.
Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence.
Rebecca Pharaon, Isa Mambetsariev, Jeremy Fricke, Ravi Salgia.
J Thorac Dis, 2020 Nov 05; 12(9). PMID: 33145086    Free PMC article.
Review.
Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma.
Chao Wang, Ming Li, Rong Wei, Junlong Wu.
J Bone Oncol, 2020 Nov 05; 25. PMID: 33145154    Free PMC article.
Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?
Mattia Algeri, Franco Locatelli.
Ann Transl Med, 2020 Nov 05; 8(17). PMID: 33145331    Free PMC article.
De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors.
Samuel T Workenhe, Andrew Nguyen, +12 authors, Karen L Mossman.
Commun Biol, 2020 Nov 06; 3(1). PMID: 33149194    Free PMC article.
[Checkpoint inhibitors for cancer therapy].
Hilke Zander, Susanne Müller-Egert, +3 authors, Jörg Engelbergs.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2020 Oct 02; 63(11). PMID: 33001218    Free PMC article.
Review.
Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
Wenxian Wang, Zhangzhou Huang, +10 authors, Zhengbo Song.
Front Oncol, 2020 Nov 10; 10. PMID: 33163403    Free PMC article.
Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer.
Rilan Bai, Lingyu Li, +3 authors, Jiuwei Cui.
Front Oncol, 2020 Nov 10; 10. PMID: 33163406    Free PMC article.
Review.
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
Hirva Mamdani, Shadia I Jalal.
Front Cell Dev Biol, 2020 Nov 10; 8. PMID: 33163495    Free PMC article.
Review.
[The use of immune checkpoint inhibitors in routine oncology].
Julian Schardt.
Z Rheumatol, 2020 Sep 17; 79(8). PMID: 32936368    Free PMC article.
Review.
Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma.
Yanjie Zhao, Feng Shi, +4 authors, Qingkun Song.
Medicine (Baltimore), 2020 Nov 08; 99(45). PMID: 33158004    Free PMC article.
Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Soleine Medjebar, Caroline Truntzer, +7 authors, François Ghiringhelli.
Oncoimmunology, 2020 Nov 13; 9(1). PMID: 33178495    Free PMC article.
Update 2020: Management of Non-Small Cell Lung Cancer.
Mariam Alexander, So Yeon Kim, Haiying Cheng.
Lung, 2020 Nov 12; 198(6). PMID: 33175991    Free PMC article.
Review.
A novel scoring method based on RNA-Seq immunograms describing individual cancer-immunity interactions.
Yukari Kobayashi, Yoshihiro Kushihara, +2 authors, Kazuhiro Kakimi.
Cancer Sci, 2020 Aug 19; 111(11). PMID: 32810311    Free PMC article.
Functional and clinical significance of ROR1 in lung adenocarcinoma.
Giovanna Schiavone, Samantha Epistolio, +5 authors, Luciano Wannesson.
BMC Cancer, 2020 Nov 12; 20(1). PMID: 33172431    Free PMC article.
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Filippo G Dall'Olio, Francesca Abbati, +7 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2020 Nov 17; 12. PMID: 33193825    Free PMC article.
Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer.
Paolo Andrea Zucali, Nadia Cordua, +4 authors, Armando Santoro.
Front Oncol, 2020 Nov 17; 10. PMID: 33194654    Free PMC article.
Review.
The Resistance Mechanisms of Lung Cancer Immunotherapy.
Fen Wang, Shubin Wang, Qing Zhou.
Front Oncol, 2020 Nov 17; 10. PMID: 33194652    Free PMC article.
Review.
Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Hongmei Liu, Dongmei Xu, +4 authors, Yuan Tian.
Front Oncol, 2020 Nov 17; 10. PMID: 33194659    Free PMC article.
Systematic Review.
Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors.
Karam Khaddour, Sandra L Gomez-Perez, +2 authors, Yanis Boumber.
Front Oncol, 2020 Nov 17; 10. PMID: 33194687    Free PMC article.
Review.
Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted.
David Rossi, Paolo Lippe, +12 authors, Paolo Alessandroni.
In Vivo, 2020 Sep 03; 34(5). PMID: 32871800    Free PMC article.
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
Xiaofeng Chen, Xiaofeng Wu, +22 authors, Yongqian Shu.
J Immunother Cancer, 2020 Nov 12; 8(2). PMID: 33172881    Free PMC article.
PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC.
Chiao-En Wu, Ching-Fu Chang, +3 authors, Yu-Chi Chiu.
Anal Cell Pathol (Amst), 2020 Nov 19; 2020. PMID: 33204603    Free PMC article.
Immunotherapy for extensive stage small cell lung cancer.
Jose M Pacheco.
J Thorac Dis, 2020 Nov 20; 12(10). PMID: 33209460    Free PMC article.
Review.
The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
Bin Wu, Shun Lu.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209600    Free PMC article.
Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy.
Zhang-Ru Yang, Mi-Na Liu, +7 authors, Xu-Wei Cai.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209626    Free PMC article.
Review.
Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review.
Wu-Yan Xia, Wen Feng, +5 authors, Xiao-Long Fu.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209631    Free PMC article.
Review.
The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer.
Yanye Wang, Shikang Zhao, Jun Chen, Song Xu.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209640    Free PMC article.
New insights into the interaction of the immune system with non-small cell lung carcinomas.
Paul Hofman.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209644    Free PMC article.
Review.
Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
Arafat Tfayli, Majd Al Assaad, +19 authors, Fadlo Khuri.
Cancer Med, 2020 Sep 30; 9(22). PMID: 32991781    Free PMC article.
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee.
Brian Gastman, Piyush K Agarwal, +30 authors, Howard L Kaufman.
J Immunother Cancer, 2020 Nov 18; 8(2). PMID: 33199512    Free PMC article.
Review.
An Innovative Immune Score-Based Prognostic Nomogram for Patients with Cervical Cancer.
Xingling Qi, Yipeng Fu, +4 authors, Guiling Li.
Biomed Res Int, 2020 Nov 24; 2020. PMID: 33224983    Free PMC article.
Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer.
Elisa Gobbini, Aurélie Swalduz, +5 authors, Pierre Saintigny.
Cancers (Basel), 2020 Oct 30; 12(11). PMID: 33114393    Free PMC article.
Review.
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Giuseppe Lamberti, Monia Sisi, +5 authors, Francesco Gelsomino.
Cancers (Basel), 2020 Oct 30; 12(11). PMID: 33114576    Free PMC article.
Review.
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.
Iosune Baraibar, Marta Roman, +23 authors, Ignacio Gil-Bazo.
Cancers (Basel), 2020 Nov 01; 12(11). PMID: 33126649    Free PMC article.
Impact of PET/CT for Assessing Response to Immunotherapy-A Clinical Perspective.
David Lang, Gerald Wahl, +4 authors, Michael Gabriel.
J Clin Med, 2020 Nov 01; 9(11). PMID: 33126715    Free PMC article.
Review.
New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives.
Ramon Andrade de Mello, Nathália Moisés Neves, +3 authors, Victor André de Almeida Zia.
J Clin Med, 2020 Nov 07; 9(11). PMID: 33153004    Free PMC article.
Review.
First line Immunotherapy for Non-Small Cell Lung Cancer.
Nicola J Nasser, Miguel Gorenberg, Abed Agbarya.
Pharmaceuticals (Basel), 2020 Nov 12; 13(11). PMID: 33171686    Free PMC article.
Review.
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Edward B Garon, Katherine B Winfree, +5 authors, Maurice Pérol.
Support Care Cancer, 2020 Apr 23; 29(1). PMID: 32318871    Free PMC article.
A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion.
Brendan Horton, Stefani Spranger.
Immunity, 2018 Jul 19; 49(1). PMID: 30021140    Free PMC article.
Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.
Heinz Läubli, Stefan Dirnhofer, Alfred Zippelius.
Virchows Arch, 2018 Aug 26; 474(4). PMID: 30143868
Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice.
Katsuyuki Hotta, Kiichiro Ninomiya, Eiki Ichihara, Katsuyuki Kiura.
Int J Clin Oncol, 2018 Aug 31; 24(1). PMID: 30159691
Review.
Mechanisms of Resistance to Immune Checkpoint Blockade.
David Liu, Russell W Jenkins, Ryan J Sullivan.
Am J Clin Dermatol, 2018 Sep 28; 20(1). PMID: 30259383    Free PMC article.
Review.
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.
Miguel F Sanmamed, Lieping Chen.
Cell, 2018 Oct 06; 175(2). PMID: 30290139    Free PMC article.
Highly Cited. Review.
Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.
Emmett V Schmidt.
Semin Immunopathol, 2018 Oct 31; 41(1). PMID: 30374524    Free PMC article.
Review.
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer.
Junghoon Shin, Jin-Haeng Chung, +11 authors, Jong-Seok Lee.
Cancer Res Treat, 2018 Nov 16; 51(3). PMID: 30428640    Free PMC article.
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).
M Majem, O Juan, +7 authors, M Provencio.
Clin Transl Oncol, 2018 Nov 18; 21(1). PMID: 30446985    Free PMC article.
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
Julia L Boland, Qin Zhou, +16 authors, Dmitriy Zamarin.
Gynecol Oncol, 2018 Nov 25; 152(2). PMID: 30470581    Free PMC article.
The lung microenvironment: an important regulator of tumour growth and metastasis.
Nasser K Altorki, Geoffrey J Markowitz, +5 authors, Vivek Mittal.
Nat Rev Cancer, 2018 Dec 12; 19(1). PMID: 30532012    Free PMC article.
Highly Cited. Review.
Reversal of resistance to chemotherapy following anti-programmed cell death-1 immunotherapy in metastatic lung adenocarcinoma: A case report.
Xiaoli Liu, Huaimin Liu, Suxia Luo.
Medicine (Baltimore), 2018 Dec 14; 97(49). PMID: 30544423    Free PMC article.
Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer.
Francois Ghiringhelli, Caroline Truntzer.
Oncotarget, 2018 Dec 20; 9(93). PMID: 30564294    Free PMC article.
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Sung Won Lim, Myung-Ju Ahn.
Korean J Intern Med, 2019 Jan 08; 34(1). PMID: 30612418    Free PMC article.
Review.
Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
Corey C Foster, David J Sher, +4 authors, Matthew Koshy.
Radiat Oncol, 2019 Jan 30; 14(1). PMID: 30691492    Free PMC article.
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
Jonathan J Havel, Diego Chowell, Timothy A Chan.
Nat Rev Cancer, 2019 Feb 14; 19(3). PMID: 30755690    Free PMC article.
Highly Cited. Review.
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
J Corral, M Majem, +7 authors, M P López Criado.
Clin Transl Oncol, 2019 Feb 17; 21(9). PMID: 30771085
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects.
Long Long, Chen Zhao, +3 authors, Honglei Chen.
Clin Drug Investig, 2019 Feb 20; 39(4). PMID: 30778885
Review.
Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects.
Chenfei Zhou, Jun Zhang.
Front Med, 2019 Feb 24; 13(1). PMID: 30796606
Review.
Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer.
Yuichi Ozawa, Yusuke Amano, +8 authors, Takafumi Suda.
Med Oncol, 2019 Mar 03; 36(4). PMID: 30825015
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.
Helen Adderley, Fiona H Blackhall, Colin R Lindsay.
EBioMedicine, 2019 Mar 11; 41. PMID: 30852159    Free PMC article.
Highly Cited. Review.
Clinical development of targeted and immune based anti-cancer therapies.
N A Seebacher, A E Stacy, G M Porter, A M Merlot.
J Exp Clin Cancer Res, 2019 Apr 13; 38(1). PMID: 30975211    Free PMC article.
Review.
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.
Hiroaki Akamatsu, Kiichiro Ninomiya, +30 authors, Nobuyuki Yamamoto.
Int J Clin Oncol, 2019 May 03; 24(7). PMID: 31049758    Free PMC article.
Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials.
Alberto Carretero-González, David Lora, +4 authors, Guillermo de Velasco.
Oncotarget, 2019 May 31; 10(35). PMID: 31143375    Free PMC article.
Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer.
Ji Hyun Park, Byoung Soo Kwon, +4 authors, Jae Cheol Lee.
J Cancer Res Clin Oncol, 2019 May 31; 145(7). PMID: 31144157
Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis.
Leyin Zhang, Leitao Sun, +8 authors, Shanming Ruan.
Biomed Res Int, 2019 Jun 20; 2019. PMID: 31214620    Free PMC article.
Systematic Review.
Advances in cancer immunotherapy 2019 - latest trends.
Stephan Kruger, Matthias Ilmer, +12 authors, Michael von Bergwelt-Baildon.
J Exp Clin Cancer Res, 2019 Jun 21; 38(1). PMID: 31217020    Free PMC article.
Highly Cited. Review.
New emerging targets in cancer immunotherapy: the role of TIM3.
Alex Friedlaender, Alfredo Addeo, Giuseppe Banna.
ESMO Open, 2019 Jul 06; 4(Suppl 3). PMID: 31275616    Free PMC article.
Review.
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" Series.
Matteo Lambertini, Matthias Preusser, Christoph C Zielinski.
ESMO Open, 2019 Jul 06; 4(Suppl 3). PMID: 31275617    Free PMC article.
Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.
Anna S Berghoff, Beatriz Bellosillo, +8 authors, Christoph C Zielinski.
ESMO Open, 2019 Jul 13; 4(3). PMID: 31297240    Free PMC article.
Review.
The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis.
Heli Shang, Zewen Zhang, +7 authors, Yuan Tian.
Medicine (Baltimore), 2019 Jul 28; 98(30). PMID: 31348245    Free PMC article.
Systematic Review.
Comparison of tumor cell numbers and 22C3 PD-L1 expression between cryobiopsy and transbronchial biopsy with endobronchial ultrasonography-guide sheath for lung cancer.
Ken Arimura, Mitsuko Kondo, +5 authors, Etsuko Tagaya.
Respir Res, 2019 Aug 20; 20(1). PMID: 31420048    Free PMC article.
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.
Juan-Miguel Cejalvo, Wolfgang Jacob, +14 authors, Andrés Cervantes.
ESMO Open, 2019 Aug 20; 4(4). PMID: 31423336    Free PMC article.
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment.
Shang-Hung Chen, Jang-Yang Chang.
Int J Mol Sci, 2019 Aug 28; 20(17). PMID: 31450627    Free PMC article.
Review.
[Use of Ommaya Reservoirs to Deliver Pemetrexed in Leptomeningeal Metastasis from Non-small Cell Lung Cancer: A Case Report and Review of the Literature].
Yongjuan Lin, Huiying Li, +2 authors, Zhenyu Yin.
Zhongguo Fei Ai Za Zhi, 2019 Aug 28; 22(8). PMID: 31451148    Free PMC article.
Review.
Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
Laurie E Steffen McLouth, Thomas W Lycan, +7 authors, W Jeffrey Petty.
Clin Lung Cancer, 2020 Jan 10; 21(3). PMID: 31917067    Free PMC article.
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.
Bassel Nazha, Subir Goyal, +9 authors, Taofeek Kunle Owonikoko.
Cancer, 2020 Sep 10; 126(23). PMID: 32902858    Free PMC article.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Hossein Borghaei, Corey J Langer, +10 authors, Shirish M Gadgeel.
Cancer, 2020 Sep 12; 126(22). PMID: 32914866    Free PMC article.
Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient.
Shinkichi Takamori, Mitsuhiro Takenoyama, +6 authors, Tatsuro Okamoto.
Thorac Cancer, 2020 Oct 17; 11(12). PMID: 33063937    Free PMC article.
Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: Design of the multicenter PGxLUNG study.
Corine de Jong, Gerarda J M Herder, Vera H M Deneer.
Thorac Cancer, 2020 Oct 20; 11(12). PMID: 33073546    Free PMC article.
Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review.
Qigu Yao, Lihu Gu, +2 authors, Hongcui Cao.
J Cell Mol Med, 2020 Oct 21; 24(22). PMID: 33078904    Free PMC article.
Systematic Review.
Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Chia-Sing Lu, Ching-Wen Lin, +10 authors, Pan-Chyr Yang.
J Immunother Cancer, 2020 Nov 28; 8(2). PMID: 33243934    Free PMC article.
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy.
Megan M Tu, Hany A Abdel-Hafiz, +10 authors, Dan Theodorescu.
Commun Biol, 2020 Nov 29; 3(1). PMID: 33247183    Free PMC article.
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
Wolfgang M Brueckl, Joachim H Ficker, Gloria Zeitler.
BMC Cancer, 2020 Dec 05; 20(1). PMID: 33272262    Free PMC article.
Review.
Changing paradigm in advanced and metastatic non-small cell lung cancer.
Dipesh Uprety, Kaushal Parikh, +2 authors, Konstantinos Leventakos.
J Thorac Dis, 2020 Dec 08; 12(11). PMID: 33282404    Free PMC article.
Review.
Radiation and immunotherapy: emerging mechanisms of synergy.
William G Breen, Konstantinos Leventakos, Haidong Dong, Kenneth W Merrell.
J Thorac Dis, 2020 Dec 08; 12(11). PMID: 33282406    Free PMC article.
Review.
Liquid biopsy is a valuable tool in the diagnosis and management of lung cancer.
Matthew J Cecchini, Eunhee S Yi.
J Thorac Dis, 2020 Dec 08; 12(11). PMID: 33282410    Free PMC article.
Review.
Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)-current consensus and future perspectives.
Doaa Said Almeldin, Jyoti Malhotra, +2 authors, Salma K Jabbour.
J Thorac Dis, 2020 Dec 08; 12(11). PMID: 33282413    Free PMC article.
Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date.
Eliana M C Tacconi, Mark Tuthill, Andrew Protheroe.
Onco Targets Ther, 2020 Dec 11; 13. PMID: 33299326    Free PMC article.
Review.
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study.
Costantino Ricci, Elisa Capizzi, +8 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2020 Dec 11; 12. PMID: 33299472    Free PMC article.
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.
Marzia Del Re, Federico Cucchiara, +13 authors, Romano Danesi.
Cancer Immunol Immunother, 2020 Dec 15; 70(6). PMID: 33315149    Free PMC article.
Immunotherapy Use in Patients With Lung Cancer and Comorbidities.
Mitchell S von Itzstein, Amrit S Gonugunta, +2 authors, David E Gerber.
Cancer J, 2020 Dec 11; 26(6). PMID: 33298724    Free PMC article.
Review.
A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy.
Tharani Krishnan, Yoko Tomita, Rachel Roberts-Thomson.
Future Sci OA, 2020 Dec 15; 6(10). PMID: 33312694    Free PMC article.
Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
Adham S Bear, Robert H Vonderheide, Mark H O'Hara.
Cancer Cell, 2020 Sep 19; 38(6). PMID: 32946773    Free PMC article.
Review.
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Paal F Brunsvig, Tormod Kyrre Guren, +7 authors, Else Marit Inderberg.
Front Immunol, 2020 Dec 17; 11. PMID: 33324397    Free PMC article.
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
Jun Sugisaka, Yukihiro Toi, +16 authors, Shunichi Sugawara.
JMA J, 2020 Dec 17; 3(1). PMID: 33324776    Free PMC article.
Emergence of a High-Plasticity Cell State during Lung Cancer Evolution.
Nemanja Despot Marjanovic, Matan Hofree, +31 authors, Tuomas Tammela.
Cancer Cell, 2020 Jul 25; 38(2). PMID: 32707077    Free PMC article.
Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
Katherine I Zhou, Bryan Peterson, +6 authors, Daniel V T Catenacci.
Clin Cancer Res, 2020 Aug 21; 26(24). PMID: 32820017    Free PMC article.
The current treatment landscape in the UK for stage III NSCLC.
Matthew Evison, AstraZeneca UK Limited.
Br J Cancer, 2020 Dec 10; 123(Suppl 1). PMID: 33293670    Free PMC article.
Review.
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).
Priyanka Patel, Doraid Alrifai, +2 authors, AstraZeneca UK Limited.
Br J Cancer, 2020 Dec 10; 123(Suppl 1). PMID: 33293672    Free PMC article.
Review.
Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.
Kamila Wojas-Krawczyk, Tomasz Kubiatowski.
Front Oncol, 2020 Dec 18; 10. PMID: 33330041    Free PMC article.
Review.
Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
Sibo Tian, Jeffrey M Switchenko, +9 authors, Kristin A Higgins.
Int J Radiat Oncol Biol Phys, 2020 Jan 27; 108(1). PMID: 31982496    Free PMC article.
Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Yusuke Kagawa, Hiromi Furuta, +10 authors, Toyoaki Hida.
Cancer Sci, 2020 Aug 10; 111(12). PMID: 32770608    Free PMC article.
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Miyako Satouchi, Kaname Nosaki, +23 authors, Katsuyuki Hotta.
Cancer Sci, 2020 Sep 15; 111(12). PMID: 32926507    Free PMC article.
DRACP: a novel method for identification of anticancer peptides.
Tianyi Zhao, Yang Hu, Tianyi Zang.
BMC Bioinformatics, 2020 Dec 17; 21(Suppl 16). PMID: 33323099    Free PMC article.
The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types.
Brianna Hoffner, Renae Vaughn, Maureen Reed, Melinda S Weber.
J Adv Pract Oncol, 2019 May 01; 10(4). PMID: 33343985    Free PMC article.
Review.
Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
Yuxin Sun, Chi Shao, +6 authors, Zuojun Xu.
Asia Pac J Clin Oncol, 2020 Aug 07; 16(6). PMID: 32757454    Free PMC article.
Review.
The rediscovery of platinum-based cancer therapy.
Sven Rottenberg, Carmen Disler, Paola Perego.
Nat Rev Cancer, 2020 Nov 01; 21(1). PMID: 33128031
Review.
Role of Surgical Intervention in Unresectable Non-Small Cell Lung Cancer.
Shigeki Suzuki, Taichiro Goto.
J Clin Med, 2020 Dec 03; 9(12). PMID: 33260352    Free PMC article.
Review.
Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer.
Veronica Ghini, Letizia Laera, +6 authors, Daniele Pozzessere.
Cancers (Basel), 2020 Dec 04; 12(12). PMID: 33265926    Free PMC article.
A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results.
Mariarosaria Sessa, Francesco Cavazzini, +2 authors, Antonio Cuneo.
Genes (Basel), 2020 Dec 09; 11(12). PMID: 33287156    Free PMC article.
Review.
Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer.
Sanjana Monirul, Marthe Rigal, +6 authors, Boris Duchemann.
Vaccines (Basel), 2020 Dec 09; 8(4). PMID: 33287161    Free PMC article.
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer.
Boris Duchemann, Jordi Remon, +10 authors, Nathalie Chaput.
Cancers (Basel), 2020 Dec 09; 12(12). PMID: 33287347    Free PMC article.
Review.
A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC.
Balazs Halmos, Thomas Burke, +4 authors, Bilal Piperdi.
Cancers (Basel), 2020 Dec 10; 12(12). PMID: 33291810    Free PMC article.
Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting.
Marcus Skribek, Konstantinos Rounis, +5 authors, Georgios Tsakonas.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33321730    Free PMC article.
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy.
Laura Boyero, Amparo Sánchez-Gastaldo, +3 authors, Reyes Bernabé-Caro.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33322522    Free PMC article.
Review.
Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer.
Andreas Hallqvist, Anna Rohlin, Sukanya Raghavan.
Scand J Immunol, 2020 Oct 06; 92(6). PMID: 33015859    Free PMC article.
Review.
PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases.
Chenglong Sun, Fei Zhou, +9 authors, Caicun Zhou.
Onco Targets Ther, 2020 Dec 29; 13. PMID: 33363383    Free PMC article.
Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study.
David Lang, Wolfgang Haslinger, +8 authors, Bernd Lamprecht.
Lung Cancer (Auckl), 2020 Dec 31; 11. PMID: 33376433    Free PMC article.
Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis.
Yuhan Wei, Yongfu Li, +5 authors, Qin Li.
J Immunol Res, 2021 Jan 01; 2020. PMID: 33381603    Free PMC article.
Systematic Review.
Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
Daniel R Principe, Matthew Narbutis, +12 authors, Ajay Rana.
Cancer Res, 2020 Apr 03; 80(15). PMID: 32238357    Free PMC article.
Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.
Pierre-Olivier Gaudreau, Marcelo V Negrao, +35 authors, Don L Gibbons.
J Thorac Oncol, 2020 Oct 24; 16(1). PMID: 33096269    Free PMC article.
Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shinkichi Takamori, Kazuki Takada, +12 authors, Masaki Mori.
Cancer Immunol Immunother, 2021 Jan 04; 70(6). PMID: 33389013
Checkpoint inhibitor immunotherapy in kidney cancer.
Wenxin Xu, Michael B Atkins, David F McDermott.
Nat Rev Urol, 2020 Feb 06; 17(3). PMID: 32020040
Review.
Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer.
Mohammad Aarif Siddiqui, Paradesi Naidu Gollavilli, +12 authors, Paolo Ceppi.
Br J Cancer, 2020 Oct 08; 124(1). PMID: 33024270    Free PMC article.
Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Yuan Tian, Aiqin Gao, +5 authors, Yuping Sun.
Front Immunol, 2021 Jan 05; 11. PMID: 33391266    Free PMC article.
Systematic Review.
Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC).
Xiaoting Ma, Yujian Zhang, Shan Wang, Jing Yu.
J Cancer, 2021 Jan 05; 12(2). PMID: 33391454    Free PMC article.
Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma.
Akihiro Nishiyama, Hiroyuki Sakaguchi, +8 authors, Seiji Yano.
Oxf Med Case Reports, 2021 Jan 05; 2020(12). PMID: 33391772    Free PMC article.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).
Paolo A Ascierto, Lisa H Butterfield, +17 authors, Igor Puzanov.
J Transl Med, 2021 Jan 08; 19(1). PMID: 33407605    Free PMC article.
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Michael Zhang, Adrian J Rodrigues, +11 authors, Gordon Li.
J Neurooncol, 2021 Jan 09; 152(1). PMID: 33415659    Free PMC article.
Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Reith R Sarkar, Nicholas J Gloude, Deborah Schiff, James D Murphy.
J Natl Cancer Inst, 2018 Dec 15; 111(7). PMID: 30551196    Free PMC article.
Crizotinib-induced immunogenic cell death in non-small cell lung cancer.
Peng Liu, Liwei Zhao, +31 authors, Guido Kroemer.
Nat Commun, 2019 Apr 04; 10(1). PMID: 30940805    Free PMC article.
Highly Cited.
Predictors of survival among Japanese patients receiving first-line chemoimmunotherapy for advanced non-small cell lung cancer.
Yuri Ogura, Nobutaka Kataoka, +7 authors, Takayuki Takeda.
Thorac Cancer, 2020 Oct 31; 12(1). PMID: 33124197    Free PMC article.
Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.
Kathryn Lurain, Ramya Ramaswami, Robert Yarchoan, Thomas S Uldrick.
Curr HIV/AIDS Rep, 2020 Aug 23; 17(5). PMID: 32827111    Free PMC article.
Review.
Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients.
Kyung-In Joung, Jong Hwa Song, +4 authors, Dong Churl Suh.
BioDrugs, 2020 Dec 18; 35(1). PMID: 33331991
Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients.
Oliver Schmalz, Christine Jacob, +6 authors, Razvan Andrei Popescu.
J Med Internet Res, 2020 Dec 22; 22(12). PMID: 33346738    Free PMC article.
Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Adrien Costantini, Paul Takam Kamga, +9 authors, Etienne Giroux Leprieur.
Cancers (Basel), 2021 Jan 06; 13(1). PMID: 33396187    Free PMC article.
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy.
Hans Raskov, Adile Orhan, Jan Pravsgaard Christensen, Ismail Gögenur.
Br J Cancer, 2020 Sep 16; 124(2). PMID: 32929195    Free PMC article.
Review.
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity.
Masashi Arita, Satoshi Watanabe, +19 authors, Toshiaki Kikuchi.
Sci Rep, 2021 Jan 14; 11(1). PMID: 33437029    Free PMC article.
Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers.
Kyoichi Kaira, Ichiei Kuji, Hiroshi Kagamu.
Cancer Imaging, 2021 Jan 15; 21(1). PMID: 33441183    Free PMC article.
Review.
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Marie Kostine, Axel Finckh, +20 authors, Thierry Schaeverbeke.
Ann Rheum Dis, 2020 Apr 25; 80(1). PMID: 32327425    Free PMC article.
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Mengze Lv, Meixia Chen, +13 authors, Zhengfan Jiang.
Cell Res, 2020 Aug 26; 30(11). PMID: 32839553    Free PMC article.
[Research Progress in the Treatment of Brain Metastases 
from Non-small Cell Lung Cancer].
Xue Han, Hongmei Li.
Zhongguo Fei Ai Za Zhi, 2020 Dec 29; 23(12). PMID: 33357316    Free PMC article.
Review.
Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis.
Qingyuan Huang, Yuzhen Zheng, +3 authors, Haiquan Chen.
J Cancer, 2021 Jan 15; 12(4). PMID: 33442411    Free PMC article.
Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events.
Ryosuke Matsukane, Hiroyuki Watanabe, +11 authors, Nobuaki Egashira.
Sci Rep, 2021 Jan 16; 11(1). PMID: 33446685    Free PMC article.
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
Sienna M Durbin, Leyre Zubiri, +11 authors, Kerry L Reynolds.
Oncologist, 2020 Oct 13; 26(1). PMID: 33044765    Free PMC article.
Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review.
Lingling Li, Fei Xu, +4 authors, Shu Xia.
BMJ Open, 2021 Jan 15; 10(11). PMID: 33444168    Free PMC article.
Systematic Review.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, +34 authors, trial investigators.
Lancet Oncol, 2019 Dec 16; 21(2). PMID: 31838015    Free PMC article.
A real-world study of the efficacy and safety of anti-programmed cell death-1 therapy combined with chemotherapy or targeted therapy in patients with advanced biliary tract cancer.
Danyang Sun, Junxun Ma, +7 authors, Yi Hu.
J Gastrointest Oncol, 2021 Jan 19; 11(6). PMID: 33457011    Free PMC article.
Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Eugene Muchnik, Kah Poh Loh, +4 authors, Ronald J Maggiore.
J Am Geriatr Soc, 2019 Jan 31; 67(5). PMID: 30698276    Free PMC article.
Highly Cited.
A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer.
Nan Qiao, Ralph Insinga, +2 authors, Martin Sénécal.
Pharmacoecon Open, 2021 Jan 21; 5(3). PMID: 33469803    Free PMC article.
Review.
TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer.
Lin Cui, Xiuqing Wang, Dekai Zhang.
Front Cell Dev Biol, 2021 Jan 21; 8. PMID: 33469538    Free PMC article.
Review.
Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Taisuke Isono, Naho Kagiyama, +9 authors, Noboru Takayanagi.
Thorac Cancer, 2020 Nov 18; 12(2). PMID: 33201587    Free PMC article.
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
M Ganzinelli, H Linardou, +14 authors, M C Garassino.
ESMO Open, 2021 Jan 11; 6(1). PMID: 33422766    Free PMC article.
Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients.
S I Rothschild, R Nachbur, +2 authors, M Pless.
ESMO Open, 2021 Jan 11; 6(1). PMID: 33422767    Free PMC article.
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Hironori Uruga, Mari Mino-Kenudson.
Virchows Arch, 2021 Jan 25; 478(1). PMID: 33486574
Review.
The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis.
Xiao-Jiang Chen, Shu-Qiang Yuan, +4 authors, Yuan-Fang Li.
Dis Markers, 2021 Jan 26; 2020. PMID: 33488843    Free PMC article.
Systematic Review.
A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player.
Yue Zhou, Fan Yu, +9 authors, Jianjiao Ni.
Transl Lung Cancer Res, 2021 Jan 26; 9(6). PMID: 33489808    Free PMC article.
Review.
Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review.
Ana Ortega-Franco, Virginia Calvo, +2 authors, Raffaele Califano.
Transl Lung Cancer Res, 2021 Jan 26; 9(6). PMID: 33489825    Free PMC article.
Review.
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer.
Wenhua Liang, Kaican Cai, +42 authors, Jianxing He.
Transl Lung Cancer Res, 2021 Jan 26; 9(6). PMID: 33489828    Free PMC article.
Review.
Chemoimmunotherapy-related enteritis resulting in a mechanical small bowel obstruction - A case report.
Ali P Mourad, Marie Shella De Robles.
Int J Surg Case Rep, 2021 Jan 18; 79. PMID: 33454633    Free PMC article.
The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer.
Long Jiang, Jia Huang, +10 authors, Qingquan Luo.
Cancer Immunol Immunother, 2021 Jan 30; 70(8). PMID: 33512555    Free PMC article.
Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology.
Robin Ristl, Nicolás M Ballarini, +3 authors, Franz König.
Pharm Stat, 2020 Aug 25; 20(1). PMID: 32830428    Free PMC article.
Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis.
Zhengbo Song, Ling Yang, +11 authors, Ming Chen.
Cell Death Dis, 2021 Jan 23; 12(1). PMID: 33479213    Free PMC article.
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Ji Hyun Park, Gun Lyung You, +21 authors, Jin Hyoung Kang.
J Cancer Res Clin Oncol, 2021 Feb 02; 147(8). PMID: 33523301
The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Fei Zhou, Meng Qiao, Caicun Zhou.
Cell Mol Immunol, 2020 Nov 13; 18(2). PMID: 33177696    Free PMC article.
Review.
Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
Yaru Tian, Xiaoyang Zhai, +2 authors, Jinming Yu.
Cancer Med, 2020 Nov 25; 10(1). PMID: 33230935    Free PMC article.
Review.
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
Ravi Salgia, Rebecca Pharaon, +2 authors, Martin Sattler.
Cell Rep Med, 2021 Feb 02; 2(1). PMID: 33521700    Free PMC article.
Review.
A programmable polymer library that enables the construction of stimuli-responsive nanocarriers containing logic gates.
Penghui Zhang, Di Gao, +15 authors, Weihong Tan.
Nat Chem, 2020 Mar 11; 12(4). PMID: 32152477
Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy.
Chuanhui Han, Anli Zhang, +2 authors, Yang-Xin Fu.
Oncogene, 2020 Dec 09; 40(5). PMID: 33288883
Review.
Effects of folic acid withdrawal on transcriptomic profiles in murine triple-negative breast cancer cell lines.
Dieuwertje E Kok, Ciara H O'Flanagan, +3 authors, Sergey A Krupenko.
Biochimie, 2020 Apr 19; 173. PMID: 32304770    Free PMC article.
Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer.
Ryan Sun, Miao Xu, +48 authors, Xihong Lin.
Genet Epidemiol, 2020 Sep 15; 45(1). PMID: 32924180    Free PMC article.
Lower Airway Dysbiosis Affects Lung Cancer Progression.
Jun-Chieh J Tsay, Benjamin G Wu, +39 authors, Leopoldo N Segal.
Cancer Discov, 2020 Nov 13; 11(2). PMID: 33177060    Free PMC article.
[Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer 
with Rare Mutation].
Teng Li, Junling Li.
Zhongguo Fei Ai Za Zhi, 2021 Jan 23; 24(1). PMID: 33478186    Free PMC article.
Review.
Immune Resistance in Lung Adenocarcinoma.
Magda Spella, Georgios T Stathopoulos.
Cancers (Basel), 2021 Jan 27; 13(3). PMID: 33494181    Free PMC article.
Review.
EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
Zhen Zhang, Hao-Xiang Wu, +4 authors, Hui-Yan Luo.
BMC Med, 2021 Feb 03; 19(1). PMID: 33526018    Free PMC article.
Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors.
Wenhui Liu, Yiping Liu, +5 authors, Zhiying Luo.
Cancer Manag Res, 2021 Feb 05; 13. PMID: 33536784    Free PMC article.
Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption.
Vaia Florou, Christopher Nevala-Plagemann, +3 authors, Ignacio Garrido-Laguna.
JCO Precis Oncol, 2021 Feb 06; 4. PMID: 33542969    Free PMC article.
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades.
Jun-Yan Li, Yu-Pei Chen, +2 authors, Jun Ma.
Mol Cancer, 2021 Feb 06; 20(1). PMID: 33541368    Free PMC article.
Review.
Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
Eric Nadler, Bhakti Arondekar, +4 authors, Vivek Pawar.
J Cancer Res Clin Oncol, 2020 Dec 03; 147(3). PMID: 33263865    Free PMC article.
Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer.
M Karayama, J Masuda, +12 authors, A Takada.
Clin Transl Oncol, 2020 Jun 14; 23(2). PMID: 32533317    Free PMC article.
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Elizabeth Dudnik, Mor Moskovitz, +11 authors, Israel Lung Cancer Group.
Oncoimmunology, 2021 Feb 09; 10(1). PMID: 33552685    Free PMC article.
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases.
Meng Qiao, Fei Zhou, +8 authors, Caicun Zhou.
Ann Transl Med, 2021 Feb 09; 9(1). PMID: 33553327    Free PMC article.

;. PMID: 33563940
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
Xiangyu Zhang, Liang Zeng, +11 authors, Nong Yang.
Cancer Immunol Immunother, 2021 Feb 11; 70(9). PMID: 33566148
Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity.
Jarrod D Predina, Andrew R Haas, +16 authors, Steven M Albelda.
Mol Ther, 2020 Nov 08; 29(2). PMID: 33160076    Free PMC article.
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Namrata S Patil, Wei Zou, +5 authors, Priti S Hegde.
PLoS One, 2021 Feb 04; 16(2). PMID: 33534859    Free PMC article.
Tailoring precision immunotherapy: coming to a clinic soon?
Shuting Han, Wai Ho Shuen, +2 authors, Han Chong Toh.
ESMO Open, 2021 Feb 10; 5 Suppl 1. PMID: 33558033    Free PMC article.
Review.
Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Da-Li Chen, Qing-Yuan Li, Qun-You Tan.
J Thorac Dis, 2021 Feb 12; 13(1). PMID: 33569202    Free PMC article.
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Alberto Pavan, Andrea Boscolo Bragadin, +16 authors, Laura Bonanno.
Transl Lung Cancer Res, 2021 Feb 12; 10(1). PMID: 33569305    Free PMC article.
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.
Doran Ksienski, Elaine S Wai, +10 authors, Mary Lesperance.
Transl Lung Cancer Res, 2021 Feb 12; 10(1). PMID: 33569318    Free PMC article.
Induction treatment in patients with stage III non-small cell lung cancer.
Ramón Palmero, Noelia Vilariño, Arturo Navarro-Martín, Ernest Nadal.
Transl Lung Cancer Res, 2021 Feb 12; 10(1). PMID: 33569335    Free PMC article.
Review.
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer.
Caroline Huynh, Logan A Walsh, Jonathan D Spicer.
Transl Lung Cancer Res, 2021 Feb 12; 10(1). PMID: 33569337    Free PMC article.
Review.
Immune checkpoint: The novel target for antitumor therapy.
Xianghu Jiang, Guohong Liu, Yirong Li, Yunbao Pan.
Genes Dis, 2019 Dec 20; 8(1). PMID: 33569511    Free PMC article.
Review.
Combinations using checkpoint blockade to overcome resistance.
Stefania Morganti, Giuseppe Curigliano.
Ecancermedicalscience, 2021 Feb 13; 14. PMID: 33574893    Free PMC article.
Review.
Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden.
Satoshi Muto, Yuki Ozaki, +18 authors, Hiroyuki Suzuki.
Oncol Lett, 2021 Feb 13; 21(3). PMID: 33574942    Free PMC article.
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Deborah Blythe Doroshow, Sheena Bhalla, +7 authors, Fred R Hirsch.
Nat Rev Clin Oncol, 2021 Feb 14; 18(6). PMID: 33580222
Review.
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.
Daniela Bruni, Helen K Angell, Jérôme Galon.
Nat Rev Cancer, 2020 Aug 06; 20(11). PMID: 32753728
Review.
Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers.
Guihua Wang, Qin Chai, +6 authors, Lin Wu.
Front Immunol, 2021 Feb 16; 11. PMID: 33584678    Free PMC article.
Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials.
Xiang Li, Shi Yan, +7 authors, Nan Wu.
Front Oncol, 2021 Feb 16; 10. PMID: 33585195    Free PMC article.
Systematic Review.
Differential Expression of PD-L1 in Central and Peripheral and TTF1-Positive and -Negative Small-Cell Lung Cancer.
Shili Yu, Meng Jia, +2 authors, Hongwen Gao.
Front Med (Lausanne), 2021 Feb 16; 7. PMID: 33585516    Free PMC article.
Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels.
Xiuhua Weng, Shaohong Luo, +5 authors, Xiongwei Xu.
Oncol Res, 2019 Oct 16; 28(2). PMID: 31610828    Free PMC article.
Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience.
Stefania Nobili, Daniele Lavacchi, +8 authors, Enrico Mini.
Oncol Res, 2019 Dec 07; 28(3). PMID: 31806078    Free PMC article.
Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1.
Anna Makowska, Selina Meier, +3 authors, Udo Kontny.
Cancer Immunol Immunother, 2020 Aug 02; 70(2). PMID: 32737537    Free PMC article.
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
Matthew D Hellmann, Pasi A Jänne, +17 authors, Peter Ordentlich.
Clin Cancer Res, 2020 Nov 19; 27(4). PMID: 33203644    Free PMC article.
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes.
Samuel I Kim, Christopher R Cassella, Katelyn T Byrne.
Front Immunol, 2021 Feb 19; 11. PMID: 33597954    Free PMC article.
Review.
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches.
Joshua Bauml, Christina Knepley.
J Adv Pract Oncol, 2021 Feb 19; 11(3). PMID: 33598322    Free PMC article.
Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer.
Tsukasa Hasegawa, Noriko Yanagitani, +8 authors, Makoto Nishio.
Int J Clin Oncol, 2020 Nov 08; 26(3). PMID: 33159605
Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
Tsz Tung Kwong, Chi Hang Wong, +4 authors, Stephen Lam Chan.
JHEP Rep, 2021 Feb 20; 3(2). PMID: 33604533    Free PMC article.
Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Shinkichi Takamori, Takefumi Komiya, Emily Powell.
Cancer Med, 2020 Dec 20; 10(3). PMID: 33340271    Free PMC article.
Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort.
Juliana Machado-Rugolo, Tabatha Gutierrez Prieto, +9 authors, Vera Luiza Capelozzi.
Pharmgenomics Pers Med, 2021 Feb 25; 14. PMID: 33623414    Free PMC article.
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Jingjing Qu, Quanhui Mei, Lijun Chen, Jianying Zhou.
Cancer Immunol Immunother, 2020 Oct 08; 70(3). PMID: 33025047    Free PMC article.
Review.
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study.
Haiping Jiang, Yulong Zheng, +13 authors, Nong Xu.
Cancer Immunol Immunother, 2020 Oct 19; 70(3). PMID: 33070260    Free PMC article.
Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4-Notch Signaling to Inhibit Angiogenesis in Lung Cancer.
Jiayin Li, Rui Han, +10 authors, Qiuye Yang.
Biomed Res Int, 2021 Feb 26; 2021. PMID: 33628824    Free PMC article.
miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors.
Florian Huemer, Michael Leisch, +2 authors, Richard Greil.
Pharmaceuticals (Basel), 2021 Feb 04; 14(2). PMID: 33530393    Free PMC article.
Review.
Comparing organ-specific immune-related adverse events for immune checkpoint inhibitors: A Bayesian network meta-analysis.
Meichen Li, Xue Hou, +5 authors, Likun Chen.
Clin Transl Med, 2021 Feb 27; 11(2). PMID: 33634972    Free PMC article.
Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival.
Sen Yang, Dongfang Tang, +9 authors, Qingyi Wei.
Cancer Immunol Immunother, 2021 Mar 03; 70(10). PMID: 33651148    Free PMC article.
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
Jingjing Qu, Quanhui Mei, +4 authors, Jianying Zhou.
Ther Adv Med Oncol, 2021 Mar 02; 13. PMID: 33643442    Free PMC article.
Review.
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).
Daniel Morgensztern, Manuel Cobo Dols, +12 authors, Teng Jin Ong.
Front Oncol, 2021 Mar 02; 10. PMID: 33643895    Free PMC article.
Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.
Alexandra L Lewis, Jamie Chaft, Monica Girotra, Gregory W Fischer.
Br J Anaesth, 2020 Feb 03; 124(3). PMID: 32007241    Free PMC article.
Review.
Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations.
Yasuhiro Kato, Gou Yamamoto, +7 authors, Hiroshi Sakai.
Int J Clin Oncol, 2021 Mar 05; 26(6). PMID: 33660106
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.
Elizabeth Dudnik, Samuel Kareff, +11 authors, Israel Lung Cancer Group.
J Immunother Cancer, 2021 Feb 19; 9(2). PMID: 33597218    Free PMC article.
Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014.
Christine M Cramer-van der Welle, Bas J M Peters, +2 authors, Ewoudt M W van de Garde.
Pharmacoecon Open, 2020 Jun 14; 5(1). PMID: 32533521    Free PMC article.
A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment.
L Leon-Mateos, M J Garcia-Velloso, +6 authors, L Gorospe.
Clin Transl Oncol, 2020 Jul 06; 23(3). PMID: 32623581    Free PMC article.
Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.
Naoki Furuya, Makoto Nishino, +6 authors, Kentaro Ito.
Thorac Cancer, 2021 Jan 16; 12(5). PMID: 33448648    Free PMC article.
Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer.
Mark N Sorial, Justin P Huynh, +4 authors, Andrew R Zullo.
Eur J Cancer, 2021 Jan 13; 145. PMID: 33431285    Free PMC article.
Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer.
H Adderley, F H Blackhall, C R Lindsay.
Cancer Immunol Immunother, 2020 Sep 12; 70(3). PMID: 32915318    Free PMC article.
Review.
Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer.
Jie Yu, QianYun Zhang, +5 authors, JinLong Yu.
Biosci Rep, 2021 Jan 26; 41(2). PMID: 33492335    Free PMC article.
Dendritic Cell-Based Immunotherapy in Lung Cancer.
Dieter Stevens, Joline Ingels, +2 authors, Karim Vermaelen.
Front Immunol, 2021 Mar 09; 11. PMID: 33679709    Free PMC article.
Review.
The Comprehensive Analyses of Genomic Variations and Assessment of TMB and PD-L1 Expression in Chinese Lung Adenosquamous Carcinoma.
Yong Cheng, Yanxiang Zhang, +7 authors, Xiaoqun Ye.
Front Genet, 2021 Mar 09; 11. PMID: 33679868    Free PMC article.
Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas.
Sijin Sun, Kailun Fei, +8 authors, Jie He.
Front Genet, 2021 Mar 09; 11. PMID: 33679869    Free PMC article.
Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.
Alberto Carretero-González, Irene Otero, +3 authors, Guillermo de Velasco.
Oncoimmunology, 2021 Mar 09; 10(1). PMID: 33680572    Free PMC article.
Systematic Review.
Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation.
Yixuan Zhou, Ingmar Niels Bastian, +30 authors, Shabnam Shalapour.
Proc Natl Acad Sci U S A, 2021 Feb 20; 118(8). PMID: 33602823    Free PMC article.
2020 Innovation-Based Optimism for Lung Cancer Outcomes.
Erin L Schenk, Tejas Patil, Jose Pacheco, Paul A Bunn.
Oncologist, 2020 Nov 13; 26(3). PMID: 33179378    Free PMC article.
Review.
Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma.
Jiayong Liu, Zhengfu Fan, +6 authors, Zhiwei Fang.
Ann Transl Med, 2021 Mar 13; 9(4). PMID: 33708966    Free PMC article.
Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer.
Sophie Stock-Martineau, Katie Laurie, +2 authors, Paul Wheatley-Price.
Curr Oncol, 2021 Mar 12; 28(1). PMID: 33704175    Free PMC article.
Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer.
Chuling Li, Meiqi Shi, +9 authors, Yong Song.
Transl Lung Cancer Res, 2021 Mar 16; 10(2). PMID: 33718021    Free PMC article.
A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer.
Chang Liu, Jing Gong, +3 authors, Jialei Wang.
Front Oncol, 2021 Mar 16; 11. PMID: 33718125    Free PMC article.
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Alessio Cortellini, Andrea De Giglio, +48 authors, Giampiero Porzio.
Thorac Cancer, 2021 Feb 03; 12(6). PMID: 33527756    Free PMC article.
[Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].
Haoyang Li, Jinghui Wang.